

ThinkEquity ®

A Boutique Investment Bank

Built Around Client's Needs

ThinkEquity was created by experienced professionals who have worked together for more than a decade, collectively financing over \$50 billion of public and private capital raises, restructurings, and mergers and acquisitions.

- ✓ Around The Clock Attention
- ✓ Identifying Solutions That Create Investor Value
- ✓ Dedicated to A Team Effort Approach



Member of:

NYSE, FINRA, &
SIPC



What We Do

Specialized & Competent

We are among the industry's best in Investment Banking and Institutional Sales, with teams dedicated to IPOs, Follow-On Offerings, Registered Direct Placements, PIPEs, select private placements and SPACs.

We also excel in Debt Capital Markets capabilities to facilitate non-dilutive financing for private and public companies.



Investment Banking

Creating Capital



Mergers & Acquisitions

Targeting & Advising



Trading

Capitalizing on Market Events



Equity Capital Markets

Issuing Shares to Fund Growth



Debt Capital Markets

Sourcing & Structuring Debt Financings



Investment Banking

- Initial Public Offerings (IPOs)
- Secondary/Follow-On Offerings
- Confidentially Marketed Public Offerings (CMPOs)
- Registered Direct Placement & PIPEs
- At-The-Market Offerings (ATMs)
- Dual Listings (Foreign Exchanges to NASDAQ & NYSE)
- Up-Listings (OTC to NASDAQ & NYSE)

Investment Banking

Advisory Services



- Initial Public Offering Preparation
- Up-Listing and Dual Listing Consultation (NASDAQ or NYSE American)
- ADR overview
- Mergers and Acquisitions (M&A) Advisory
- SPAC, IPOs, and MSA
- Fairness Opinions
- Comparable company and precedent transaction analysis
- Develop short and long-term goals focused on value creation



01 02 03


Investment Banking

Equity Syndicate

- ThinkEquity's Equity Syndicate Department coordinates the marketing and distribution of its equity offerings.
- The group builds institutional and retail syndicates for ThinkEquity's proprietary IPOs, Secondary/Follow-on and Up-Listing Offerings.
- ThinkEquity regularly participates in public offerings managed by leading Wall Street investment banks, giving its investors access to equity, preferred and SPAC offerings.
- Our equity, preferred and SPAC participations include co-manager, underwriter and selling group roles.




Our Syndicate network includes relationships developed over decades with dozens of banks & broker dealers.





Mergers & Acquisitions

- Fairness Opinions
- Valuation Analysis
- Recapitalizations & Restructuring



Equity Capital Markets & Institutional Sales

- Our investing client base consist of Mutual Funds, Hedge Funds, Family office accounts and High Net Worth
- Corporate Access & Non-Deal Roadshows
- ThinkEquity Conference & Equity Syndicate
- Institutional Sales team dedicated to equity transactions, including IPOs, Follow-On Offerings, Registered Direct Placements, PIPEs, select private placements and SPACs
- Access to over 10,000 institutions of all sizes throughout the U.S., Europe, Israel, Asia and South America
- Extensive deal and non-deal roadshow capabilities in the U.S. and Europe
- Ability to source and place large blocks of stock

2021 Non-Deal Roadshow Statistics

- Number of Companies Marketed: 60
- Number of Investor Accounts Introduced: 360
- Total Meetings: 1,370

Including International Issuers & Investors Based In:

- Belgium
- Denmark
- Germany
- Netherlands
- Sweden
- United Kingdom
- Canada
- France
- Israel
- Norway
- Switzerland
- United States




Non-Deal Roadshows & Corporate Access

- Introducing active investors and emerging growth companies through one-on-one calls and meetings.
- Investors include mutual funds, hedge funds, family offices and high net worth accounts in the U.S. and abroad.
- Companies include both under-the-radar growth stories and recently financed issuers.
- Opportunity for companies to build a knowledgeable investor base and for investors to consistently generate new investment ideas.

Debt Capital Markets

- Loans to both Public and Private Companies
- Debt Placements
- Senior Debt
- Subordinated Debt
- Unsecured Senior Debt
- Acquisition Financing
- Revolvers



ThinkEquity has structured over **\$1 billion** of debt financing for companies.

Debt Capital Markets



ThinkEquity's Debt Capital Markets group sources and structures a wide variety of non-dilutive debt financings for both private & public companies.



Working with its ever-growing network of lenders including national and regional banks, BDCs, private finance companies, hedge funds, family offices and other alternative lenders, ThinkEquity is your one-stop shop for working and growth capital needs, including acquisition financing, recapitalizations and bridge financings.



The Debt Capital Markets group has structured over \$1 billion of debt financing for companies, with a strong focus on the technology, healthcare, industrials, cleantech, fintech, specialty finance and media & entertainment sectors.



Access to a diverse network
of institutional lenders



ThinkEquity Reach

U.S. Public Issuers

Cardiff Oncology, Inc.
Second Sight Medical Products, Inc.
FAT Brands, Inc.
Polar Power, Inc.
TG Venture Acquisition Corp
Tivic Health Systems, Inc.
Immix Biopharma, Inc.
Evmo, Inc.

Harbor Custom Development, Inc.

PetVivo Holdings, Inc.

OppFi, Inc.
FG Merger Corp

Annovis Bio, Inc.
Tiziana Life Sciences
Context Therapeutics, Inc.
Vallon Pharma, Inc.
Virpax Pharma, Inc.

Stemline Therapeutics, Inc.
Staffing 360 Solutions, Inc.
1847 Goedeker Inc.
ProPhase Labs, Inc.
Ipsidy, Inc.
Marpai, Inc.

Bridgeline Digital, Inc.
iSpecimen, Inc.
TransCode Therapeutics, Inc.

BioXcel Therapeutics, Inc.

Matinas BioPharma Holdings, Inc.
OncoSec Medical Inc.
Hepion Pharma, Inc.
Hillstream BioPharma, Inc.

cbdMD, Inc.
Piedmont Lithium, Inc.
Ballantyne Strong, Inc.
Adara Acquisition Corp.

Virios Therapeutics, Inc.
Inhibikase Therapeutics, Inc.

Ontrak, Inc.
BioVie, Inc.


OMNIQ Corp.

Ampio Pharmaceuticals, Inc.
Urban-gro, Inc.
CEA Industries, Inc.

Lantern Pharma, Inc.
Kiromic BioPharma, Inc.


FlexShopper, Inc.
Cyclo Therapeutics, Inc.
SG Blocks, Inc.
Fortress Biotech, Inc.
LMP Automotive Holdings
Duos Technologies, Inc.
Blink Charging Co.
GEE Group, Inc.
Save Foods, Inc.
FG Financial Group, Inc.

BK Technologies Corp.
Twin Vee Powercats Co.
EZFill Holdings, Inc.



International Reach

ThinkEquity has active relationships with Issuers and Investors globally



- | | |
|-----------|----------------------|
| Australia | Italy |
| Belgium | Mexico |
| Brazil | Netherlands |
| Canada | Norway |
| China | Portugal |
| Czechia | South Africa |
| Denmark | Spain |
| France | Sweden |
| Germany | Switzerland |
| Greece | United Arab Emirates |
| India | United Kingdom |
| Ireland | United States |
| Israel | |

Trading

- Trading & Sales Trading
- Block Trading
- 10b-5 Sales
- Corporate Stock Buybacks
- Risk Arbitrage & Event Driven Trading



Trading

NYSE Floor Trading Overview

In order to better serve our clients and provide the best possible access to liquidity, ThinkEquity has opened an NYSE Trading Floor Operation staffed by industry veterans.



- ThinkEquity's NYSE floor trading operation provides clients with direct access to point of sale liquidity for IPOs and follow on offerings, as well as, Third Party Algo (TPA) access to the NYSE Parity order types (eQuote and dQuote).
- Our Floor Brokers trade Initial Public Offerings (IPOs), Up-listings, At-the-Market Programs (ATM's), Follow-ons, Convertibles and Derivatives, Rights Offerings, Share Repurchases/10b-18 Company Buybacks, Risk Arbitrage and Special Situations.
- ThinkEquity traders source liquidity using multiple algo strategies while having access to NYSE Parity allocation, which enables our Floor Brokers a share of incoming interest at the best price, regardless of order-entry time. Brokers can utilize multiple execution strategies simultaneously, combining algos with d-quote, reserve, darkpools, layering, etc.
- Our trading professionals deliver both high and low-touch services to help our clients develop trading strategies to execute transactions across exchanges globally.

Equity Research



ThinkEquity's proprietary research platform focuses on discovering and analyzing exciting emerging growth companies in a variety of business sectors.



Our research team strives to be the “go to” source of information for each company under coverage and its particular industry.

Sector Focus

Technology

Media

Telecom

Healthcare

Industrials

Consumer

Energy

Financials

More



Private Client Group

Whether you are planning for retirement, to fund a college education, or you want to speculate or trade your account, we offer investors a wide range of financial products to meet your financial and strategic objectives. For the sophisticated, accredited investor we also provide access to proprietary investment opportunities, such as private placements of debt and equity securities. Each investor's goals are unique.

- **Equities**
- **Fixed-Income**
- **Mutual Funds**
- **Private Placements**

Products and Services for Unique Financial Needs





The ThinkEquity Standard

- We only represent clients we believe in – people and businesses that we feel will make a difference.
- Our goal is to identify opportunities that others can't see and create superior value.
- We work intensely and endlessly for our clients no matter the difficulties at hand.
- Our goal is to deliver superior returns and achievements for investors and issuers.
- We stimulate and develop solutions in difficult situations, creating an atmosphere of optimism and pride in every aspect of our business.
- We perform at the highest ethical standards in our work for our clients.
- Our goal is to recognize the constantly changing environment ahead of the herd and evaluate and implement those changes rapidly and timely.
- Our goal is to be the best.

ThinkEquity Conference

The Mandarin Oriental Hotel
New York, NY

October 26, 2022

Who Should Attend

- U.S. & International Public & Private Companies
- Industry Executives
- Institutional Investors
- Accredited Investors
- Private Equity & Venture Capital

Sectors:

AI/Big Data

Biotechnology

Metals & Mining

Oil & Gas

Technology

EV/ EV Infrastructure

Conference Overview:

70+

Company Presentations

700+

Attendees

500+

1-on-1 Investor Meetings




Premium Networking Opportunities



Ramnarain “Joe” Jaigobind

Chief Executive Officer

Joe Jaigobind has been in the financial services arena for over 30 years. He and his team have originated and raised in excess of \$60 billion in capital markets transactions as the Sole Book Runner, Joint, Co-Manager, or as a Syndicate Member. He began his career at Shearson Lehman American Express in the Private Client Group. He later served as Senior Vice President with Investec Ernest & Co, Head of Capital Markets for Rodman & Renshaw, and was an Executive Managing Director & Head of Capital Markets at Maxim Group. Over the past three decades, Mr. Jaigobind created and built investment banking, equity capital markets, and institutional sales departments at many boutique firms. Mr. Jaigobind was a Chairman's Circle Member of the US-India Business Council and was a Director on the Board of the US-Pakistan Business Council. He was also a member of the Susquehanna Investment Network based in Lewisburg, PA. Mr. Jaigobind has previously served on the Board of Directors of Care Management International.



William Baquet

President & COO

Mr. Baquet has more than thirty-five years of executive leadership and investment banking experience and has been involved in the successful financing of a broad range of public and private companies. He began his Wall Street career at Haas Securities Corporation, a NYSE Member Firm and later served as President, Chief Executive Officer and Investment Banker at Berkeley Securities Corporation. Following Berkeley, Mr. Baquet joined Commonwealth Associates' investment banking team where he was instrumental in the financing and structuring of numerous highly successful telecommunications and technology projects. Since 1997, Mr. Baquet has served as President and Chief Executive Officer of Fordham Financial Management, Inc. where he developed, managed, and expanded all aspects of the full-service broker-dealer.

Chirag Choudhary

Head of Equity Capital Markets & Institutional Sales

Mr. Choudhary's career on Wall Street spans over 17 years when he started at Merrill Lynch & Co. in the Private Client Group conducting portfolio reviews for existing clients utilizing the firm's proprietary platform. Following Merrill Lynch, he worked for Investec Ernst & Co., a leading international bank, and after that as partner and Senior Vice President at Maxim Group, LLC where he helped manage and expand the firm's Equity Syndicate Department. After Maxim, Mr. Choudhary was Senior Vice President at Rodman & Renshaw, LLC, with a focus on raising capital for emerging growth companies with a focus in healthcare and technology. Most recently Mr. Choudhary worked for Aegis Capital & Joseph Gunnar & Co., LLC as Head of Institutional Sales and built and expanded the firm's institutional sales desk. He has been involved in over 300 transactions raising in excess of \$10 billion. As Head of Capital Markets and Institutional Sales at ThinkEquity, he will continue to develop and maintain relationships with clients and help the firm grow in all aspects. Chirag is a Series 7 and 66 licensed Registered Representative and a Series 24 licensed General Securities Principal. Mr. Choudhary received a Master's Degree in Business Administration (Finance) from Hawaii Pacific University and a Degree in Commerce (Hons.) (Finance and Tax Planning) from University of Delhi. He was a member of Chairman's Circle of U.S-India Chamber of Commerce (NY chapter). Mr. Choudhary is also a member of Asia Society, a leading international non-profit educational organization founded in 1956 with headquarters in New York and a presence in 6 countries. He is also involved with the charities Hudson Union Society of New York, September 2001 Memorial Foundation, NY and RobinHood.

Eric Lord

Head of Investment Banking

Mr. Lord began his career as an investment analyst for a registered investment advisory firm in Boston where he prepared asset allocation plans and annual investment performance reviews for high net-worth clients. Mr. Lord was also Vice President of Equity Capital Markets at Maxim Group LLC. Over a two-year span at Maxim, he worked on more than 150 public market offerings, including eight Maxim lead managed transactions. Following Maxim, he joined Rodman & Renshaw, LLC as Senior Vice President of Global Equity Capital Markets at Rodman & Renshaw, LLC. In his more than three years at Rodman, which spanned the financial crisis, he assisted in the origination and sale of nearly 100 public offerings, including more than 25 lead-managed public offerings, as well as several lead-managed private placements. Mr. Lord was Senior Vice President at Aegis Capital Corp. and a founding member of the firm's Global Equity Capital Markets department. During his four years with Aegis, the Global Equity Capital Markets department completed more than 100 offerings as book-runner or co-manager, raising nearly \$3 billion in gross proceeds. Most recently, Mr. Lord was Head of Investment Banking at Joseph Gunnar & Co. Mr. Lord is a Series 7 licensed Registered Representative, Series 24 licensed General Securities Principal and passed the CFA Level 1 exam. Mr. Lord holds a B.S. in Business Administration with a concentration in Finance from the University of Richmond.

Craig M. Skop

Managing Director, Corporate & Executive Services

Mr. Skop has been a Wall Street professional for over 20 years. He is responsible for all Corporate Access at ThinkEquity. Prior to ThinkEquity, Mr. Skop was at Joseph Gunnar as a Senior Vice President in the Global Equity Capital Markets Group. Prior to joining Joseph Gunnar & Co., LLC, Mr. Skop spent 10 years at Aegis Capital Corp., most recently as a Senior Vice President of Global Equity Capital Markets and previously on the Equity Sales Desk. Mr. Skop spent the earlier part of his career on the Equity Sales Desks at Oppenheimer and Shearson Lehman, managing assets for institutional and high net-worth clients. Mr. Skop is a Series 7 and Series 63 licensed Registered Representative. Mr. Skop has received a Business Administration Degree from Florida Atlantic University.

Kevin Mangan

Managing Director, Head of Equity Syndicate

Mr. Mangan has more than 12 years of experience in the securities industry serving in management positions in Equity Capital Markets, Investment Banking and Equity Syndicate. As Managing Director and Head of Equity Syndicate of ThinkEquity, he is responsible for coordinating ThinkEquity's proprietary public and private offerings while maintaining relationships with leading investment banks to facilitate the firm's participation in syndicated offerings. Prior to ThinkEquity, Mr. Mangan was Senior Vice President of Investment Banking at Joseph Gunnar & Co. Kevin started his career as Syndicate Manager at Maxim Group LLC. During his time at Maxim, Mr. Mangan was involved in all aspects of the firm's syndicate business. Following Maxim, Kevin was Vice President, Syndicate Manager of Global Equity Capital Markets at Rodman & Renshaw, LLC. In over three years at Rodman, Mr. Mangan assisted in the origination, marketing and execution of nearly 100 public offerings, including over 25 lead-managed public offerings, as well as several lead-managed private placements. Prior to joining Joseph Gunnar, Mr. Mangan was Vice President, Syndicate Manager at Aegis Capital Corp and a founding member of the firm's Global Equity Capital Markets department. In four years with Aegis, the Global Equity Capital Markets department completed over 100 offerings as book-runner or co-manager, raising nearly \$3 billion in gross proceeds. Mr. Mangan is a Series 7 licensed Registered Representative and Series 24 licensed General Securities Principal. He holds a B.S. in Business Administration with a concentration in Management from the University of Miami.

Philip Quartuccio

Managing Director, Head of Global Trading

Mr. Quartuccio runs ThinkEquity's global trading operations including the NYSE Trading Floor. Mr. Quartuccio has over 20 years of trading experience including running his own NYSE floor brokerage firm, Illustro Trading. He has held senior positions at Janney Montgomery Scott, Arnhold & S. Bleichroeder and most recently Tullet Prebon ICAP. As a member of the NYSE technology committee, Mr. Quartuccio has extensive experience with the NYSE's trading technology. This experience includes the development of the NYSE Third Party Algo (TPA) program that enables algorithmic access to the NYSE Parity order types for quantitative automated trading. Mr. Quartuccio holds FINRA Series 7, 19, 24, 62, and 63 registrations.

Jeffrey Singer

Head of Debt Capital Markets

Mr. Singer has been involved in the successful financing of a broad range of public and private companies across almost every industry with a strong focus on technology, energy, specialty finance/FinTech, IT services, digital commerce, ed-tech, healthcare services and consumer brands. Jeff specializes in structuring debt financings for emerging growth companies to maximize their funding availability while minimizing dilution to shareholders.

Mr. Singer works with a vast network of lenders including specialty banks, private finance companies, hedge funds, BDCs, venture lenders, family offices and other alternative lenders to structure and place debt financings of all sizes for his client base. Jeff works with company management teams to analyze their balance sheets and capital needs to determine the various options available and to find the most attractive and surest path to closing. Debt structures include cash flow financing, asset based loans, loans against IP, loans against contracts and purchase orders, enterprise value loans as well as other alternative structures.

































Prior to joining ThinkEquity, Mr. Singer served as Head of Debt Capital Markets at Joseph Gunnar & Co. for two years and as Managing Director of Dragonfly Capital Partners, where he ran the New York office of the firm for over 10 years. Jeff has structured over one billion dollars of debt financing proposals over the course of his career. Mr. Singer holds a BS from University of Wisconsin and his MBA from Fordham University Graduate School of Business.

Ashok Kumar

Head of Equity Research

































Mr. Kumar joined ThinkEquity in 2018, continuing his distinguished 20 plus year career in equity research. Mr. Kumar has held senior research positions at Joseph Gunnar & Co., Aegis Capital, Rodman & Renshaw, and Maxim Group. Mr. Kumar also held senior analyst positions at Raymond James, Piper Jaffray, and Prudential Securities. Prior to his career in research, specializing in the technology and healthcare sectors, Mr. Kumar worked in engineering and marketing at Intel Corporation. Having been cited in various publications such as The Wall Street Journal, The New York Times, USA Today, Business Week, and Fortune, as well as being regularly featured on CNBC and Bloomberg, Mr. Kumar was named one of Smart Magazine's 30 Most Influential People in Investing in 2000. Mr. Kumar received a Bachelor's Degree in Engineering from the Indian Institute of Technology, a Master's Degree in Electrical Engineering from Purdue University, and a Master's Degree in Business Administration from the Wharton School of the University of Pennsylvania.

Recent Transactions

United Infrastructure Holdings, Inc.  \$20,000,000 Debt Financing June 13, 2022	EZRaider  \$880,000 Debt Financing June 10, 2022	SaverOne 2014 Ltd.  \$13,010,000 U.S. Initial Public Offering June 2, 2022	OKYO Pharma Ltd.  \$2,500,000 Follow-On Offering May 16, 2022	Snow Lake Resources Ltd.  \$18,000,000 Follow-On Offering April 7, 2022	Permex Petroleum Corporation  \$7,500,000 Private Placement March 28, 2022	OMNIQ Corp.  \$8,500,000 Debt Financing March 25, 2022	Piedmont Lithium Inc.  \$130,800,000 Follow-On Offering March 22, 2022
FG Merger Corp.  \$80,500,000 Initial Public Offering February 25, 2022	CEA Industries Inc.  \$24,000,000 Follow-On Offering February 10, 2022	Hillstream BioPharma, Inc.  \$15,000,000 Initial Public Offering January 11, 2022	Immix Biopharma, Inc.  \$24,150,000 Initial Public Offering December 15, 2021	Hagerty, Inc. and Aldel Financial Inc.  \$3,130,000,000 Business Combination December 2, 2021	Context Therapeutics Inc.  \$31,250,000 Private Placement December 1, 2021	iSpecimen Inc.  \$21,000,000 Private Placement November 29, 2021	Snow Lake Resources Ltd.  \$27,600,000 Initial Public Offering November 18, 2021
Tivic Health Systems, Inc.  \$17,250,000 Initial Public Offering November 10, 2021	Zoomcar, Inc.  \$92,000,000 Private Placement November 8, 2021	TG Venture Acquisition Corp.  \$115,000,000 Initial Public Offering November 2, 2021	Siyata Mobile Inc.  \$6,000,000 Debt Financing October 27, 2021	FAT Brands Inc.  \$18,000,000 8.25% Series B Cumulative Preferred Stock October 27, 2021	Marpai, Inc.  \$28,750,000 Initial Public Offering October 26, 2021	FG Financial Group, Inc.  \$2,600,000 Follow-On Offering October 25, 2021	Context Therapeutics Inc.  \$28,750,000 Follow-On Offering October 19, 2021
Harbor Custom Development, Inc  \$41,400,000 8% Series A Cumulative Convertible Preferred Stock October 4, 2021	EzFill Holdings, Inc.  \$28,750,000 Initial Public Offering September 14, 2021	Virpax Pharmaceuticals, Inc.  \$40,000,000 Follow-On Offering September 14, 2021	authID.ai  \$11,500,000 Follow-On Offering August 23, 2021	ProPhase Labs, Inc.  \$14,600,000 Acquisition of Nebula Genomics August 11, 2021	PetVivo Holdings, Inc.  \$11,250,000 Follow-On Offering August 10, 2021	BioVie Inc.  \$20,000,000 Follow-On Offering August 8, 2021	Draganfly Inc.  \$20,000,000 Follow-On Offering July 29, 2021

































01 02 03 04 05 06 07 08

Recent Transactions

<p>Opportunity Financial, LLC and FG New America Acquisition Corp.</p>  <p>\$800,000,000 Business Combination July 20, 2021</p>	<p>Twin Vee PowerCats Co.</p>  <p>\$18,000,000 Initial Public Offering July 20, 2021</p>	<p>Red Cat Holdings, Inc.</p>  <p>\$60,000,000 Follow-On Offering July 18, 2021</p>	<p>Pyxis Tankers, Inc.</p>  <p>\$6,200,000 7.75% Series A Cumulative Convertible Preferred Stock July 14, 2021</p>	<p>EVmo, Inc.</p>  <p>\$15,000,000 Debt Financing July 12, 2021</p>	<p>TransCode Therapeutics, Inc.</p>  <p>\$28,750,000 Initial Public Offering July 8, 2021</p>	<p>OMNIQ Corp.</p>  <p>\$15,000,000 Private Placement July 8, 2021</p>	<p>Kiromic BioPharma, Inc.</p>  <p>\$40,000,000 Follow-On Offering June 29, 2021</p>
<p>cbdMD, Inc.</p>  <p>\$16,500,000 8% Series A Cumulative Convertible Preferred Stock June 28, 2021</p>	<p>Second Sight Medical Products, Inc.</p>  <p>\$57,500,000 Follow-On Offering June 22, 2021</p>	<p>FAT Brands Inc.</p>  <p>\$9,200,000 8.25% Series B Cumulative Preferred Stock June 17, 2021</p>	<p>iSpecimen Inc.</p>  <p>\$20,700,000 Initial Public Offering June 16, 2021</p>	<p>Inhibikase Therapeutics, Inc.</p>  <p>\$45,000,000 Follow-On Offering June 15, 2021</p>	<p>Harbor Custom Development, Inc.</p>  <p>\$31,500,000 8% Series A Cumulative Convertible Preferred Stock June 9, 2021</p>	<p>BK Technologies Corporation</p>  <p>\$12,800,000 Follow-On Offering June 6, 2021</p>	<p>Trasir Therapeutics, Inc./Auris Medical Holding Ltd.</p>  <p>Acquisition June 3, 2021</p>
<p>BriaCell Therapeutics Corp.</p>  <p>\$27,200,000 Private Placement June 3, 2021</p>	<p>1847 Goedecker Inc.</p>  <p>\$70,000,000 Debt Financing June 2, 2021</p>	<p>1847 Goedecker Inc.</p>  <p>\$209,500,000 Follow-On Offering May 27, 2021</p>	<p>Annovis Bio, Inc.</p>  <p>\$50,000,000 Follow-On Offering May 23, 2021</p>	<p>FG Financial Group, Inc.</p>  <p>\$4,900,000 8% Series A Cumulative Preferred Stock May 18, 2021</p>	<p>Save Foods, Inc.</p>  <p>\$12,000,000 Follow-On Offering May 13, 2021</p>	<p>Red Cat Holdings, Inc.</p>  <p>\$16,000,000 Follow-On Offering April 29, 2021</p>	<p>Gee Group Inc.</p>  <p>\$57,500,000 Follow-On Offering April 14, 2021</p>
<p>Aldel Financial Inc.</p>  <p>\$115,000,000 Initial Public Offering April 8, 2021</p>	<p>Second Sight Medical Products, Inc.</p>  <p>\$27,900,000 Private Placement March 24, 2021</p>	<p>Piedmont Lithium Limited</p>  <p>\$122,500,000 Follow-On Offering March 23, 2021</p>	<p>LMP Automotive Holdings, Inc.</p>  <p>\$20,000,000 Private Placement February 24, 2021</p>	<p>BriaCell Therapeutics Corp.</p>  <p>\$28,700,000 Follow-On Offering February 23, 2021</p>	<p>Pyxis Tankers, Inc.</p>  <p>\$25,000,000 Private Placement February 17, 2021</p>	<p>Virpax Pharmaceuticals Inc.</p>  <p>\$18,000,000 Initial Public Offering February 16, 2021</p>	<p>Hepion Pharmaceuticals, Inc.</p>  <p>\$88,400,000 Follow-On Offering February 16, 2021</p>
































01 02 03 04 05 06 07 08

Recent Transactions

<p>Nano Dimension Ltd.</p>  <p>\$500,000,000 Registered Direct February 15, 2021</p>	<p>urban-gro, Inc.</p>  <p>\$62,000,000 Follow-On Offering February 11, 2021</p>	<p>Vallon Pharmaceuticals, Inc.</p>  <p>\$18,000,000 Initial Public Offering February 9, 2021</p>	<p>Adara Acquisition Corp.</p>  <p>\$115,000,000 Initial Public Offering February 8, 2021</p>	<p>Polar Power, Inc.</p>  <p>\$13,500,000 Follow-On Offering February 7, 2021</p>	<p>Ballantyne Strong, Inc.</p>  <p>\$7,600,000 Follow-On Offering February 3, 2021</p>	<p>OncoSec Medical Incorporated</p>  <p>\$42,000,000 Follow-On Offering January 21, 2021</p>	<p>ProPhase Labs, Inc.</p>  <p>\$37,500,000 Follow-On Offering January 18, 2021</p>
<p>Lantern Pharma Inc.</p>  <p>\$69,000,000 Follow-On Offering January 14, 2021</p>	<p>Nano Dimension Ltd.</p>  <p>\$332,500,000 Registered Direct January 13, 2021</p>	<p>Harbor Custom Development, Inc.</p>  <p>\$27,600,000 Follow-On Offering January 12, 2021</p>	<p>Blink Charging Co.</p>  <p>\$232,060,000 Follow-On Offering January 8, 2021</p>	<p>United Infrastructure Holdings, Inc.</p>  <p>\$20,000,000 Preferred Equity & Senior Debt January 4, 2021</p>	<p>Nano Dimension Ltd.</p>  <p>\$250,000,000 Registered Direct December 27, 2020</p>	<p>Inhibikase Therapeutics, Inc.</p>  <p>\$18,000,000 Initial Public Offering December 22, 2020</p>	<p>Virios Therapeutics, Inc.</p>  <p>\$34,500,000 Initial Public Offering December 16, 2020</p>
<p>ENDRA Life Sciences Inc.</p>  <p>\$5,500,000 Follow-On Offering December 15, 2020</p>	<p>cbdMD, Inc.</p>  <p>\$17,250,000 8% Series A Cumulative Convertible Preferred Stock December 8, 2020</p>	<p>Nano Dimension Ltd.</p>  <p>\$180,000,000 Registered Direct December 6, 2020</p>	<p>Nano Dimension Ltd.</p>  <p>\$60,000,000 Registered Direct November 29, 2020</p>	<p>Hepion Pharmaceuticals, Inc.</p>  <p>\$34,500,000 Follow-On Offering November 24, 2020</p>	<p>Vision Marine Technologies Inc.</p>  <p>\$27,600,000 Initial Public Offering November 23, 2020</p>	<p>Nano Dimension Ltd.</p>  <p>\$100,000,000 Registered Direct November 19, 2020</p>	<p>Nano Dimension Ltd.</p>  <p>\$50,200,000 Registered Direct October 26, 2020</p>
<p>Piedmont Lithium Ltd.</p>  <p>\$57,500,000 Follow-On Offering October 21, 2020</p>	<p>Kiromic BioPharma, Inc.</p>  <p>\$15,000,000 Initial Public Offering October 15, 2020</p>	<p>Pyxis Tankers Inc.</p>  <p>\$5,000,000 7.75% Series A Cumulative Convertible Preferred Stock October 8, 2020</p>	<p>Nano Dimension Ltd.</p>  <p>\$16,900,000 Registered Direct September 30, 2020</p>	<p>FG New America Acquisition Corp.</p>  <p>\$238,000,000 Initial Public Offering September 29, 2020</p>	<p>BioVie Inc.</p>  <p>\$18,000,000 Follow-On Offering September 17, 2020</p>	<p>SG Blocks, Inc. and Clarity Diagnostics</p>  <p>Financial Advisor Joint Venture September 1, 2020</p>	<p>Harbor Custom Development, Inc.</p>  <p>\$12,200,000 Initial Public Offering August 28, 2020</p>



01 02 03 04 05 06 07 08

Recent Transactions

<p>GreenPower Motor Company, Inc.</p>  <p>\$37,200,000 U.S. Initial Public Offering August 28, 2020</p>	<p>Fortress Biotech, Inc.</p>  <p>\$13,200,000 Series A Cumulative Redeemable Preferred Stock August 26, 2020</p>	<p>Ontrak, Inc. (fka Catasys, Inc.)</p>  <p>\$48,875,000 Series A Cumulative Perpetual Preferred Stock August 21, 2020</p>	<p>OncoSec Medical Incorporated</p>  <p>\$15,000,000 Registered Direct August 16, 2020</p>	<p>Tiziana Life Sciences plc</p>  <p>\$57,300,000 Registered Direct August 3, 2020</p>	<p>1847 Goedecker Inc.</p> <p>GOEDEKER'S</p> <p>\$10,000,000 Initial Public Offering July 30, 2020</p>	<p>Fat Brands, Inc.</p>  <p>\$9,000,000 8.25% Series B Cumulative Preferred Stock July 13, 2020</p>	<p>Lantern Pharma Inc.</p>  <p>\$26,300,000 Initial Public Offering June 10, 2020</p>
<p>Piedmont Lithium Ltd.</p>  <p>\$20,500,000 Follow-On Offering June 8, 2020</p>	<p>Fortress Biotech, Inc.</p>  <p>\$11,500,000 Series A Cumulative Redeemable Preferred Stock May 26, 2020</p>	<p>Nano Dimension Ltd.</p>  <p>\$35,900,000 Registered Direct May 20, 2020</p>	<p>Medigus Ltd.</p>  <p>\$5,000,000 Follow-On Offering May 19, 2020</p>	<p>SG Blocks, Inc.</p>  <p>\$17,300,000 Follow-On Offering May 6, 2020</p>	<p>SG Blocks, Inc. and OSANG Healthcare Co., Ltd.</p>  <p>Distribution Agreement May 5, 2020</p>	<p>Second Sight Medical Products, Inc.</p>  <p>\$7,500,000 Follow-On Offering April 30, 2020</p>	<p>Nano Dimension Ltd.</p>  <p>\$13,300,000 Follow-On Offering April 22, 2020</p>
<p>Tiziana Life Sciences plc</p>  <p>\$20,000,000 ATM Offering April 10, 2020</p>	<p>Fortress Biotech, Inc.</p>  <p>\$5,000,000 Series A Preferred Repurchase Program March 23, 2020</p>	<p>Tiziana Life Sciences plc</p>  <p>\$10,000,000 Follow-On Offering March 12, 2020</p>	<p>Ampio Pharmaceuticals, Inc.</p>  <p>\$50,000,000 ATM Offering February 21, 2020</p>	<p>Duos Technologies Group, Inc.</p>  <p>\$9,300,000 Follow-On Offering February 12, 2020</p>	<p>Fortress Biotech, Inc.</p>  <p>\$14,400,000 9.375% Series A Cumulative Redeemable Preferred Stock February 11, 2020</p>	<p>LMP Automotive Holdings Inc.</p>  <p>\$19,200,000 Follow-On Offering February 11, 2020</p>	<p>OncoSec Medical, Inc.</p>  <p>\$30,000,000 Strategic Investment February 10, 2020</p>
<p>Nano Dimension Ltd.</p>  <p>\$3,900,000 Follow-On Offering February 5, 2020</p>	<p>Annovis Bio, Inc.</p>  <p>\$13,800,000 Initial Public Offering January 31, 2020</p>	<p>cbdMD, Inc.</p>  <p>\$18,400,000 Follow-On Offering January 10, 2020</p>	<p>Better Choice Company</p>  <p>\$47,000,000 M&A December 20, 2019</p>	<p>SG Blocks, Inc.</p>  <p>\$2,200,000 Follow-On Offering December 10, 2019</p>	<p>Drone Aviation Corp/COMSovereign</p>  <p>\$78,000,000 Merger December 4, 2019</p>	<p>LMP Automotive Holdings, Inc.</p>  <p>\$13,200,000 Initial Public Offering December 4, 2019</p>	<p>Fortress Biotech, Inc.</p>  <p>\$6,000,000 Series A Cumulative Redeemable Preferred Stock November 25, 2019</p>

































01 02 03 04 05 06 07 08

Recent Transactions

<p>cbdMD, Inc.</p>  <p>\$5,000,000 Series A Cumulative Convertible Preferred Stock October 10, 2019</p>	<p>BioXcel Therapeutics, Inc.</p>  <p>\$19,000,000 Follow-On Offering September 26, 2019</p>	<p>Stemline Therapeutics, Inc.</p>  <p>\$87,600,000 Follow-On Offering August 9, 2019</p>	<p>Ampio Pharmaceuticals, Inc.</p>  <p>\$12,000,000 Registered Direct June 17, 2019</p>	<p>CTD Holdings, Inc.</p>  <p>\$7,400,000 Private Placement May 31, 2019</p>	<p>OncoSec Medical Incorporated</p>  <p>\$11,000,000 Follow-On Offering May 28, 2019</p>	<p>Immuron Limited</p>  <p>\$2,000,000 Follow-On Offering May 23, 2019</p>	<p>cbdMD, Inc.</p>  <p>\$13,800,000 Follow-On Offering May 13, 2019</p>
<p>GreenPower Motor Company</p>  <p>\$4,000,000 Private Placement May 3, 2019</p>	<p>OMNIQ Corp.</p>  <p>\$5,000,000 Private Placement April 4, 2019</p>	<p>ElectraMeccanica Vehicles Corp.</p>  <p>\$12,000,000 Registered Direct March 26, 2019</p>	<p>Bridgeline Digital</p>  <p>\$10,000,000 Private Placement March 13, 2019</p>	<p>Kingsway Financial Services Inc. & Geminus Holding Company, Inc.</p>  <p>\$10,000,000 Senior Acquisition Debt Financing March 4, 2019</p>	<p>Staffing 360 Solutions, Inc.</p>  <p>\$4,800,000 Follow-On Offering February 8, 2019</p>	<p>Stemline Therapeutics, Inc.</p>  <p>\$92,000,000 Follow-On Offering January 15, 2019</p>	<p>Precision Opinion</p>  <p>\$4,800,000 Senior Secured Term Loan January 14, 2019</p>
<p>Mynd Analytics & Emmaus Life Sciences</p>  <p>Fairness Opinion January 3, 2019</p>	<p>Level Brands, Inc. & cbdMD</p>  <p>\$120,000,000 Fairness Opinion December 21, 2018</p>	<p>Frost & Sullivan</p>  <p>\$3,000,000 Credit Facility November 26, 2018</p>	<p>ReWalk Robotics Ltd.</p>  <p>\$13,300,000 Follow-On Offering November 16, 2018</p>	<p>Cuentas Inc.</p>  <p>\$4,000,000 Factoring Agreement November 9, 2018</p>	<p>ElectraMeccanica Vehicles Corp.</p>  <p>\$8,500,000 Registered Direct November 7, 2018</p>	<p>Novume Solutions, Inc.</p>  <p>\$3,300,000 Follow-On Offering October 29, 2018</p>	<p>Wize Pharma, Inc.</p>  <p>\$4,500,000 Private Placement October 23, 2018</p>
<p>Bridgeline Digital, Inc.</p>  <p>\$5,000,000 Follow-On Offering October 17, 2018</p>	<p>Spectrum Global Solutions, Inc.</p>  <p>\$5,000,000 Credit Facility October 12, 2018</p>	<p>OMNIQ Corp.</p>  <p>\$6,300,000 M&A October 11, 2018</p>	<p>Level Brands, Inc.</p>  <p>\$6,900,000 Follow-On Offering September 28, 2018</p>	<p>FlexShopper, Inc.</p>  <p>\$10,000,000 Follow-On Offering September 25, 2018</p>	<p>ElectraMeccanica Vehicles Corp.</p>  <p>\$10,000,000 Follow-On Offering August 8, 2018</p>	<p>HealthLynked Corp.</p>  <p>\$2,000,000 Private Placement July 19, 2018</p>	<p>Matinas Biopharma</p>  <p>\$8,000,000 Registered Direct June 19, 2018</p>




01 02 03 04 05 06 07 08

Recent Transactions

Trovogene, Inc.  \$18,000,000 Follow-On Offering June 7, 2018	Shared Labs, Inc  \$10,000,000 Senior Debt Financing April 10, 2018	Toughbuilt Industries, Inc.  \$800,000 Private Placement March 15, 2018	Immuron Limited  \$5,100,000 Private Placement March 14, 2018	Aytu Biosciences, Inc  \$12,900,000 Follow-On Offering March 1, 2018	Spectrum Global Solutions Adex Corporation  \$6,200,000 Senior/Junior Acquisition Debt Financing February 27, 2018	Blink Charging Co.  \$18,500,000 Follow-On Offering February 13, 2018	Shared Labs, Inc.  \$15,000,000 Working Capital Financing February 9, 2018
OncoSec Medical Incorporated  \$23,000,000 Follow-On Offering February 6, 2018	Stemline Therapeutics, Inc.  \$51,800,000 Follow-On Offering January 24, 2018	Longfin Corp.  \$52,700,000 Private Placement January 23, 2018	Absolutdata Technologies, Inc.  \$2,700,000 Debt Capital January 9, 2018	Teamtronics, Inc.  \$3,300,000 Acquisition Debt Financing January 9, 2018	Akers Biosciences, Inc.  \$6,900,000 Follow-On Offering December 18, 2017	Akoustis Technologies, Inc.  \$14,600,000 Private Placement December 15, 2017	Pyxis Tankers Inc.  \$4,800,000 Private Placement December 6, 2017
Duos Technologies Group, Inc.  \$11,000,000 Private Placement November 21, 2017	Level Brands, Inc.  \$12,000,000 Initial Public Offering November 17, 2017	Sachem Capital Corp.  \$17,000,000 Follow-On Offering October 25, 2017	Ampio Pharmaceuticals, Inc.  \$6,800,000 Registered Direct October 16, 2017	Hamamatsu Photonics  \$42,000,000 M&A September 22, 2017	Precision Opinion, Inc.  \$4,300,000 Debt Capital September 19, 2017	BiondVax Pharmaceuticals Ltd.  \$10,000,000 Follow-On Offering September 14, 2017	China Cord Blood Corp.  \$30,000,000 10b5 Stock Sale August 28, 2017
Aytu BioScience, Inc.  \$11,800,000 Private Placement August 15, 2017	Shared Labs, Inc.  \$12,000,000 Acquisition Debt Financing August 11, 2017	Meridian Waste Solutions  \$4,000,000 Follow-On Offering June 28, 2017	SG Blocks, Inc.  \$8,600,000 Initial Public Offering June 21, 2017	Immuron Limited  \$6,100,000 Initial Public Offering June 8, 2017	Ampio Pharmaceuticals  \$6,300,000 Private Placement June 2, 2017	MRI Interventions, Inc.  \$13,300,000 Private Placement May 25, 2017	Staffing 360 Solutions, Inc.  \$3,000,000 ATM Offering May 11, 2017

01 02 03 04 05 06 07 08

Recent Transactions

<p>Arkados</p>  <p>\$15,000,000 M&A May 8, 2017</p>	<p>Arkados</p>  <p>\$4,000,000 Private Placement May 8, 2017</p>	<p>Ontrak, Inc. (fka Catasys, Inc.)</p>  <p>\$16,500,000 Follow-On Offering April 25, 2017</p>	<p>Sorrento Therapeutics</p>  <p>\$47,300,000 Follow-On Offering April 13, 2017</p>	<p>AVEO Pharmaceuticals, INC.</p>  <p>\$15,500,000 Follow-On Offering March 31, 2017</p>	<p>Akers Biosciences, Inc.</p>  <p>\$2,000,000 Private Placement March 30, 2017</p>	<p>Pareteum Corp.</p>  <p>\$3,500,000 Follow-On Offering March 10, 2017</p>	<p>Micronet</p>  <p>\$3,000,000 Senior Secured Credit Facility March 1, 2017</p>
<p>Sachem Capital Corp</p>  <p>\$13,000,000 Initial Public Offering February 10, 2017</p>	<p>Meridian Waste Solutions</p>  <p>\$12,400,000 Follow-On Offering January 24, 2017</p>	<p>Stemline Therapeutics, Inc.</p>  <p>\$45,000,000 Follow-On Offering January 20, 2017</p>	<p>Akoustis</p>  <p>\$10,000,000 Private Placement January 18, 2017</p>	<p>Akers Biosciences, Inc.</p>  <p>\$2,000,000 Follow-on Direct January 10, 2017</p>	<p>AMERI Holdings, Inc.</p>  <p>\$5,000,000 Capital Restructuring Consulting December 30, 2016</p>	<p>Polar Power, Inc.</p>  <p>\$19,300,000 Initial Public Offering December 7, 2016</p>	<p>Delivery Agent</p>  <p>M&A November 18, 2016</p>
<p>Sysorex</p>  <p>\$10,000,000 Senior Secured Credit Facility November 1, 2016</p>	<p>Aytu BioScience, Inc.</p>  <p>\$8,600,000 Secondary/Follow-On October 27, 2016</p>	<p>ToughBuilt Industries, Inc.</p>  <p>\$6,100,000 Private Placement October 17, 2016</p>	<p>Drone Company</p>  <p>\$1,500,000 Senior Term Loan October 14, 2016</p>	<p>Optex Systems Holdings, Inc.</p>  <p>\$4,800,000 Follow-on Direct August 22, 2016</p>	<p>Sorrento Therapeutics, Inc.</p>  <p>\$200,000,000 Fairness Opinion August 15, 2016</p>	<p>Sorrento Therapeutics, Inc.</p>  <p>\$70,000,000 Fairness Opinion August 8, 2016</p>	<p>Collect Biotechnology Ltd.</p>  <p>\$8,400,000 Initial Public Offering July 29, 2016</p>
<p>Aytu BioScience, Inc.</p>  <p>\$10,500,000 Common Stock Purchase Agreement July 28, 2016</p>	<p>Rennova Health, Inc.</p>  <p>\$8,600,000 Secondary/Follow-On July 14, 2016</p>	<p>Kitov Pharmaceuticals Holdings Ltd.</p>  <p>\$12,000,000 Secondary/Follow-On June 29, 2016</p>	<p>Intellicheck Mobilisa, Inc.</p>  <p>\$2,100,000 Secondary/Follow-On June 15, 2016</p>	<p>Aytu BioScience, Inc.</p>  <p>\$7,500,000 Secondary/Follow-On May 3, 2016</p>	<p>Chalkable</p>  <p>\$3,000,000 Bank/Venture Debt Term Loan April 20, 2016</p>	<p>340B Technologies</p>  <p>\$2,000,000 Senior Secured Term Loan April 18, 2016</p>	<p>Staffing 360 Solutions, Inc.</p>  <p>\$2,000,000 Registered Direct April 3, 2016</p>

01 02 03 04 05 06 07 08

Recent Transactions

LabStyle Innovations
Corp.


































\$8,500,000

Secondary/Follow-On

March 4, 2016

Selected Past IPOs

<p>FG Merger Corp.</p>  <p>\$80,500,000 Initial Public Offering February 25, 2022</p>	<p>Hillstream BioPharma, Inc.</p>  <p>\$15,000,000 Initial Public Offering January 11, 2021</p>	<p>Immix Biopharma, Inc.</p>  <p>\$24,150,000 Initial Public Offering December 15, 2021</p>	<p>Snow Lake Resources Ltd.</p>  <p>\$27,600,000 Initial Public Offering November 18, 2021</p>	<p>Tivic Health Systems, Inc.</p>  <p>\$17,250,000 Initial Public Offering November 10, 2021</p>	<p>TG Venture Acquisition Corp.</p>  <p>\$115,000,000 Initial Public Offering November 2, 2021</p>	<p>Marpai, Inc.</p>  <p>\$28,750,000 Initial Public Offering October 26, 2021</p>	<p>Context Therapeutics Inc.</p>  <p>\$28,750,000 Initial Public Offering October 19, 2021</p>
<p>EzFill Holdings, Inc.</p>  <p>\$28,750,000 Initial Public Offering September 14, 2021</p>	<p>Twin Vee PowerCats Co.</p>  <p>\$18,000,000 Initial Public Offering July 20, 2021</p>	<p>TransCode Therapeutics, Inc.</p>  <p>\$28,750,000 Initial Public Offering July 8, 2021</p>	<p>iSpecimen Inc.</p>  <p>\$20,700,000 Initial Public Offering June 16, 2021</p>	<p>Aldel Financial Inc.</p>  <p>\$115,000,000 Initial Public Offering April 8, 2021</p>	<p>Virpax Pharmaceuticals Inc.</p>  <p>\$18,000,000 Initial Public Offering February 16, 2021</p>	<p>Vallon Pharmaceuticals, Inc.</p>  <p>\$18,000,000 Initial Public Offering February 9, 2021</p>	<p>Adara Acquisition Corp.</p>  <p>\$115,000,000 Initial Public Offering February 8, 2021</p>
<p>Inhibikase Therapeutics, Inc.</p>  <p>\$18,000,000 Initial Public Offering December 22, 2020</p>	<p>Virios Therapeutics, Inc.</p>  <p>\$34,500,000 Initial Public Offering December 16, 2020</p>	<p>Vision Marine Technologies Inc.</p>  <p>\$27,600,000 Initial Public Offering November 23, 2020</p>	<p>Kiromic BioPharma, Inc.</p>  <p>\$15,000,000 Initial Public Offering October 15, 2020</p>	<p>FG New America Acquisition Corp.</p>  <p>\$238,000,000 Initial Public Offering September 29, 2020</p>	<p>Harbor Custom Development, Inc.</p>  <p>\$12,200,000 Initial Public Offering August 28, 2020</p>	<p>GreenPower Motor Company, Inc.</p>  <p>\$37,200,000 U.S. Initial Public Offering August 28, 2020</p>	<p>1847 Goedecker Inc.</p>  <p>\$10,000,000 Initial Public Offering July 30, 2020</p>
<p>Lantern Pharma Inc.</p>  <p>\$26,300,000 Initial Public Offering June 10, 2020</p>	<p>Annovis Bio, Inc.</p>  <p>\$13,800,000 Initial Public Offering January 31, 2020</p>	<p>LMP Automotive Holdings, Inc.</p>  <p>\$13,200,000 Initial Public Offering December 4, 2019</p>	<p>Level Brands, Inc.</p>  <p>\$12,000,000 Initial Public Offering November 17, 2017</p>	<p>SG Blocks, Inc.</p>  <p>\$8,600,000 Initial Public Offering June 21, 2017</p>	<p>Immuron</p>  <p>\$6,100,000 Initial Public Offering June 8, 2017</p>	<p>Sachem Capital Corp</p>  <p>\$13,000,000 Initial Public Offering February 10, 2017</p>	<p>Polar Power, Inc.</p>  <p>\$19,300,000 Initial Public Offering December 7, 2016</p>

Selected Past IPOs

<p>Ritter Pharmaceuticals, Inc.</p>  <p>\$20,000,000 Initial Public Offering June 24, 2015</p>	<p>Jaguar Animal Health, Inc.</p>  <p>\$20,000,000 Initial Public Offering May 13, 2015</p>	<p>BiondVax Pharmaceuticals Ltd.</p>  <p>\$9,600,000 Initial Public Offering May 11, 2015</p>	<p>EyeGate Pharmaceuticals, Inc.</p>  <p>\$4,100,000 Initial Public Offering February 12, 2015</p>	<p>Medical Transcription Billing, Corp.</p>  <p>\$20,400,000 Initial Public Offering July 23, 2014</p>	<p>GlobeImmune, Inc.</p>  <p>\$15,000,000 Initial Public Offering July 1, 2014</p>	<p>Signal Genetics, Inc.</p>  <p>\$8,500,000 Initial Public Offering June 17, 2014</p>	<p>Aldeyra Therapeutics, Inc.</p>  <p>\$12,000,000 Initial Public Offering May 1, 2014</p>
<p>1347 Property Insurance Holdings, Inc.</p>  <p>\$17,400,000 Initial Public Offering March 31, 2014</p>	<p>Recro Pharma, Inc.</p>  <p>\$34,500,000 Initial Public Offering March 6, 2014</p>	<p>Semler Scientific, Inc.</p>  <p>\$10,000,000 Initial Public Offering February 20, 2014</p>	<p>NephroGenex, Inc.</p>  <p>\$37,200,000 Initial Public Offering February 10, 2014</p>	<p>Biocept, Inc.</p>  <p>\$19,000,000 Initial Public Offering February 4, 2014</p>	<p>Akers Biosciences, Inc.</p>  <p>\$15,000,000 Initial Public Offering January 23, 2014</p>	<p>Evoke Pharma, Inc.</p>  <p>\$29,000,000 Initial Public Offering September 25, 2013</p>	<p>Heat Biologics, Inc.</p>  <p>\$27,000,000 Initial Public Offering July 23, 2013</p>
<p>xG Technologies, Inc.</p>  <p>\$8,500,000 Initial Public Offering July 18, 2013</p>	<p>Alcobra Ltd.</p>  <p>\$25,000,000 Initial Public Offering May 22, 2013</p>	<p>Cancer Genetics, Inc.</p>  <p>\$6,900,000 Initial Public Offering April 4, 2013</p>	<p>Professional Diversity Network, Inc.</p>  <p>\$21,000,000 Initial Public Offering March 5, 2013</p>	<p>Stemline Therapeutics, Inc.</p>  <p>\$38,200,000 Initial Public Offering January 29, 2013</p>			

Nasdaq Up-Listing Offering Case Studies

Nasdaq: SVRE, SVREW | TASE: SAVR



\$13,000,000
U.S. Initial Public Offering
June 2, 2022

-
- In June 2022, SaverOne 2014 Ltd. (Nasdaq: SVRE, SVREW | TASE: SAVR) raised \$13.0 million in an underwritten public offering which listed the Company onto the Nasdaq.
 - The Company priced the public offering of 3,150,200 units consisting of one ADSs (or Pre-Funded Warrant in lieu thereof) and one warrant at a public offering price of \$4.13 per unit. ThinkEquity acted as sole book-running manager for the offering.

01 02 03 04 05 06 07 08 09 10 11

Nasdaq Up-Listing Offering Case Studies



\$2,500,000
Follow-On Offering
May 16, 2022

- In May 2022, OKYO Pharma Ltd. (Nasdaq: OKYO | LSE: OKYO) raised \$2.5 million in an underwritten public offering which listed the Company onto the Nasdaq.
- The Company priced the public offering of 625,000 ADSs at a public offering price of \$4.00 per ADS. ThinkEquity acted as sole book-running manager for the offering.



\$24,000,000
Follow-On Offering
February 10, 2022

- In February 2022, CEA Industries Inc. (Nasdaq: CEAD, CEADW) raised \$24 million in an underwritten public offering which listed the Company onto the Nasdaq.
- The Company priced the public offering of 5,811,138 shares of its common stock and warrants to purchase up to 5,811,138 shares of the Company's common stock at a combined public offering price of \$4.13 per share and warrant. ThinkEquity acted as sole book-running manager for the offering.

Nasdaq Up-Listing Offering Case Studies



\$11,500,000

Follow-On Offering

August 23, 2021



\$11,250,000

Follow-On Offering

August 10, 2021

- In August 2021, authID.ai (Nasdaq: AUID) raised \$11.50 million in an underwritten public offering which listed the Company onto the Nasdaq.
- The Company priced the public offering of 1,642,856 shares of its common stock at a public offering price of \$7.00 per share. ThinkEquity acted as sole book-running manager for the offering.

- In August 2021, PetVivo Holdings, Inc. (Nasdaq: PETV, PETVW) raised \$11.25 million in an underwritten public offering which listed the Company onto the Nasdaq.
- The Company priced the public offering of 2,500,000 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock, at a public offering price of \$4.50. ThinkEquity acted as sole book-running manager for the offering.

Nasdaq Up-Listing Offering Case Studies



\$20,000,000
Follow-On Offering
July 29, 2021

- In July 2021, Draganfly Inc. (Nasdaq: DPRO) raised \$20 million in an underwritten public offering which listed the Company onto the Nasdaq.
- The Company priced the public offering of 5,000,000 shares of its common stock at a public offering price of \$4.00 per share. ThinkEquity acted as sole book-running manager for the offering.



\$12,000,000
Follow-On Offering
May 13, 2021

- Save Foods, Inc. (Nasdaq: SVFD) raised \$12 million in May 2021 in a public offering which listed the Company onto the Nasdaq.
- The Company sold 1,090,909 shares of the Company's common stock at a public offering price of \$11.00 per share.

Nasdaq Up-Listing Offering Case Studies



\$60,000,000
Follow-On Offering
July 18, 2021

\$16,000,000
Follow-On Offering
April 29, 2021

- Red Cat Holdings, Inc. (Nasdaq: RCAT) raised \$16 million in April 2021 in a public offering which listed the Company onto the Nasdaq.
- The Company sold 4,000,000 shares of the Company's common stock at a public offering price of \$4.00 per share.
- Three months later, the Company raised an additional \$60 million in a follow-on offering of common stock priced at \$4.50 per share.



\$27,200,000
Private Placement
June 3, 2021

\$28,700,000
Follow-On Offering
February 23, 2021

- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW | TSXV: BCT) raised \$25 million in February 2021 in a public offering which listed the Company onto the Nasdaq.
- The Company sold 5,882,353 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock, at a public offering price of \$4.25 per unit.
- On April 12th 2021, BriaCell announced the closing of the over-allotment option in connection with February's offering. An additional 882,352 shares at the public offering price of \$4.24 per share for gross proceeds of \$3.7 million was raised.
- In June 2021, ThinkEquity acted as placement agent for a private placement for BriaCell, raising \$27.2 million at a price of \$5.26 per share and one warrant.

Nasdaq Up-Listing Offering Case Studies

urban-gro[®]

\$62,000,000
Follow-On Offering
February 11, 2021

- In February 2021, urban-gro, Inc. (Nasdaq: UGRO) raised \$62.1 million, including the underwriter's full exercise of over-allotment option, in a public offering which listed the Company onto the Nasdaq.
- The Company sold 6,210,000 shares of the Company's common stock at a public offering price of \$10.00 per share, which includes 810,000 shares sold upon full exercise of the underwriter's option to purchase additional shares.

biovie

\$20,000,000 \$18,000,000
Follow-On Offering Follow-On Offering
August 8, 2021 September 17, 2020

- In September 2020, BioVie Inc. (Nasdaq: BIVI) raised \$15.7 million in a common stock public offering which listed the Company onto Nasdaq.
- The underwriters exercised the full over-allotment option, increasing the offering size to \$18 million.
- The net proceeds from the offering eliminated the Company's outstanding indebtedness and will fund clinical trials for its lead drug candidate, an orphan drug for the treatment of ascites due to advanced liver cirrhosis.
- In August 2021, ThinkEquity acted as the sole book-running manager in a follow-on public offering, raising \$20 million at a price of \$8.00 per share.

Nasdaq Up-Listing Offering Case Studies



\$37,200,000

US Initial Public Offering

August 28, 2020

\$4,000,000

Private Placement

May 3, 2019



\$9,300,000

Follow-On Offering

February 12, 2020

\$11,000,000

Private Placement

November 21, 2017

- In May 2019, ThinkEquity acted as placement agent for GreenPower Motor Company Inc. (Nasdaq: GP), then listed on the TSX-V and OTCQX, raising \$4.0 million in a private placement priced at \$2.14 per share and half warrant (split adjusted).
- In August 2020, the common stock traded as high as \$23.45, a return of 1,838% on the private placement unit.
- In August 2020, GreenPower raised \$37.2 million in a common stock US initial public offering priced at \$20.00 per share which listed the company onto Nasdaq.

- In November 2017, Duos Technologies Group, Inc. (Nasdaq: DUOT) raised \$11.0 million in a private placement.
- In January 2020, Duos completed a reverse split of its shares of common stock at a ratio of 1-for-14 in connection with future up-listing.
- In February 2020, raised \$9.3 million in a common stock public offering which listed the company onto Nasdaq.

Nasdaq Up-Listing Offering Case Studies



\$1,360,000 Follow-On Offering July 17, 2019	\$2,000,000 Follow-On Offering May 23, 2019
\$5,100,000 Private Placement March 13, 2018	\$6,100,000 US Initial Public Offering June 8, 2017

- Immuron Limited (Nasdaq: IMRN, IMRNW | ASE: IMC) raised \$6.1 million of common stock in June 2017 for its US Initial Public Offering, listing the company's shares on Nasdaq.
- In March 2018, the company raised an additional \$5.1 million in a private placement of common stock and warrants.
- From May 2019 to July 2019, the company raised an aggregate of \$3.4 million in two public offerings of common stock without warrants to fund the advancement of additional drug candidates under a new CEO.



\$48,900,000 Series A Cumulative Perpetual Preferred Stock Offering August 26, 2020	\$16,458,000 Follow-On Offering April 25, 2017
--	--

- Ontrak, Inc. (fka Catasys, Inc.) (Nasdaq: OTRK) raised \$16.5 million in April 2017 in a common stock public offering which listed the company on Nasdaq (no warrants).
- Converted approximately \$8 million of debt and liabilities to equity in connection with the offering, leaving the company debt free and increased total stockholders equity to \$9 million from a deficit of \$25 million pre-offering.
- Average daily trading volume increased from approximately 6,900 shares in the year prior to the offering to 56,000 shares in the year following the offering.
- Entered into a \$10 million debt financing agreement in June 2018, where: \$7.5 million came from Horizon Technology Finance Corporation (Nasdaq: HRZN) and \$2.5 million from Heritage Bank of Commerce.
- Expanded upon the June 2018 debt financing with Horizon Technology Finance Corporation by adding an additional \$7.5 million to the agreement.
- In August 2020, the Company raised \$48.9 million in a public offering of non-convertible preferred stock, including the full exercise of the overallotment option.

Nasdaq Up-Listing Offering Case Studies



\$11,000,000
Follow-on Offering
March 27, 2017

\$6,500,000
Follow-On Offering
July 23, 2015

- Cryoport, Inc. (Nasdaq: CYRX, CYRXW) raised \$6.5 million in July 2015 in a common stock and warrants public offering which listed the company on Nasdaq.
- In March of 2017, Cryoport raised \$11,000,000 in a common stock follow-on offering (no warrants).
- Since the July 2015 Up-Listing, the company has raised \$333.4 million through common stock offerings, rights offerings and warrant tender offers
- Cryoport's common stock has appreciated as much as 2,426% from the up-listing price, with its market cap surpassing \$3.0 billion.



\$14,000,000
Follow-On Offering
December 18, 2014

- Abeona Therapeutics, Inc. (Nasdaq: ABEO, ABEOW) raised \$14 million in December 2014 in a common stock and warrants public offering which listed the company on Nasdaq.
- Nine months later, Abeona Therapeutics raised \$15 million in an offering of common stock and warrants at a 37.5% premium to the unit offering price.
- In October of 2016, the company raised \$42 million of common stock (no warrants).
- In October of 2017, the company raised \$80 million of common stock at \$16 (no warrants).
- The company has since raised approximately \$134 million in equity offerings as the common stock appreciated as much as 436% from the up-listing price.

Nasdaq Up-Listing Offering Case Studies

sorrento

\$47,300,000 Follow-On Offering April 13, 2017	\$200,000,000 Fairness Opinion August 15, 2016	\$70,000,000 Fairness Opinion August 8, 2016
\$28,800,000 Follow-On Offering May 14, 2014	\$17,700,000 Block Trade December 19, 2013	\$34,600,625 Follow-On Offering October 24, 2013

- Sorrento Therapeutics, Inc. (Nasdaq: SRNE) raised \$34.6 million in October 2013 in a common stock public offering which listed the company on Nasdaq.
- The offering was originally marketed with 50% tradable warrants, but halfway through the roadshow, the warrant component of the offering was removed. The pricing date was also accelerated by four days.
- Two months later in December 2013, the our team led the sale of a block of \$17.7 million worth of common stock from OPKO Health, one of Sorrento's early investors, to institutional investors.
- Five months later in May 2014, Sorrento raised \$28 million in a common stock offering to institutional investors (no warrants).
- The stock price appreciated as much as 270% from the initial offering price.
- The company has since sold its drug candidate Cynviloq™ for up to \$1.3 billion to NantPharma, raised and additional \$47.3 million from the sale of common stock and made multiple acquisitions.



ADVAXIS

\$14,100,000 Follow-On Offering March 26, 2014	\$26,450,000 Follow-On Offering October 16, 2013
--	--

- Advaxis, Inc. (Nasdaq: ADXS, ADXSW) raised \$26.5 million in October 2013 in a common stock plus 50% tradable warrants public offering which listed the company on Nasdaq.
- Five months later in March 2014, Advaxis raised another \$12 million in a common stock offering (without warrants).
- Nine months later in December 2014, Advaxis raised \$17 million in a registered direct offering of common shares (without warrants) to institutional investors.
- Two months later in February 2015, Advaxis raised \$23 million in a registered direct offering of common shares (without warrants) to institutional investors.
- Two months later in April 2015, Advaxis raised \$53 million in an underwritten public offering of common stock (without warrants).
- Four months later in August 2015, Advaxis raised \$25 million from a strategic investor in a common stock sale (without warrants).

*ADXS prices shown on a pre-reverse split basis for comparison to the \$4.00 2013 public offering price

01 02 03 04 05 06 07 08 09 10 11

Nasdaq Up-Listing Offering Case Studies



\$10,000,000
Follow-On Offering
October 26, 2012

- > Xplore Technologies Corp. (Nasdaq: XPLR) raised \$10 million in October 2012 in a common stock public offering at \$5.00 per share which listed the company on Nasdaq (without warrants).
- > In March 2015, the company raised another \$13 million in an underwritten common stock public offering (without warrants).
- > In July 2018, the company was acquired by Zebra Technologies, a \$9 billion market cap company, for \$90 million or \$6 per share, a 20% premium to the initial offering price.



\$51,800,000
Follow-On Offering
May 4, 2012

\$17,250,000
Follow-On Offering
December 1, 2011

- > Synergy Pharmaceuticals, Inc. (Nasdaq: SGYP, SGYPW) raised \$17 million in December 2011 in a common stock plus 50% tradable warrants public offering which listed the company on Nasdaq.
- > Five months later in May 2012, Synergy raised another \$52 million in an underwritten common stock offering (without warrants).
- > Eleven months later in April 2013, Synergy raised another \$90 million in an underwritten common stock offering (without warrants).
- > Eleven months later in March 2014, Synergy put an at-the-market offering in place to raise up to \$50 million through offerings of common stock (without warrants).
- > Eight months later in November 2014, Synergy raised over \$200 million through the issuance of Convertible Senior Notes.
- > The Company received FDA approval for their drug TRULANCE® in January 2018.

01 02 03 04 05 06 07 08 09 10 11

Past Nasdaq Up-Listing Offerings

<p>SaverOne 2014 Ltd.</p>  <p>\$13,000,000 U.S. Initial Public Offering June 2, 2022</p>	<p>OKYO Pharma Ltd.</p>  <p>\$2,500,000 Follow-On Offering May 16, 2022</p>	<p>CEA Industries Inc.</p>  <p>\$24,000,000 Follow-On Offering February 10, 2022</p>	<p>authID.ai</p>  <p>\$11,500,000 Follow-On Offering August 23, 2021</p>	<p>PetVivo Holdings, Inc.</p>  <p>\$11,250,000 Follow-On Offering August 10, 2021</p>	<p>Draganfly Inc.</p>  <p>\$20,000,000 Follow-On Offering July 29, 2021</p>	<p>Save Foods, Inc.</p>  <p>\$12,000,000 Follow-On Offering May 13, 2021</p>	<p>Red Cat Holdings, Inc.</p>  <p>\$16,000,000 Follow-On Offering April 29, 2021</p>
<p>BriaCell Therapeutics Corp.</p>  <p>\$28,700,000 Follow-On Offering February 23, 2021</p>	<p>urban-gro, Inc.</p>  <p>\$62,000,000 Follow-On Offering February 11, 2021</p>	<p>BioVie Inc.</p>  <p>\$18,000,000 Secondary/Follow-On September 17, 2020</p>	<p>GreenPower Motor Company, Inc.</p>  <p>\$37,200,000 U.S. Initial Public Offering August 28, 2020</p>	<p>Duos Technologies Group, Inc.</p>  <p>\$9,300,000 Follow-On Offering February 12, 2020</p>	<p>ElectraMeccanica Vehicles Corp.</p>  <p>\$10,000,000 Follow-On Offering August 8, 2018</p>	<p>Blink Charging Co.</p>  <p>\$18,500,000 Follow-On Offering February 13, 2018</p>	<p>AYTU BioScience, Inc.</p>  <p>\$11,800,000 Private Placement August 15, 2017</p>
<p>Immuron</p>  <p>\$6,100,000 Initial Public Offering June 8, 2017</p>	<p>Ontrak, Inc. (fka Catasys, Inc.)</p>  <p>\$16,500,000 Follow-On Offering April 25, 2017</p>	<p>Meridian Waste Solutions</p>  <p>\$12,400,000 Follow-On Offering January 24, 2017</p>	<p>EyeGate Pharmaceuticals, Inc.</p>  <p>\$10,000,000 Secondary/Follow-On July 31, 2015</p>	<p>Cryoport, Inc.</p>  <p>\$6,500,000 Secondary/Follow-On July 23, 2015</p>	<p>Abeona Therapeutics, Inc. (fka PlasmaTech Biopharmaceuticals)</p>  <p>\$14,000,000 Secondary/Follow-On December 18, 2014</p>	<p>Collectar Biosciences, Inc.</p>  <p>\$12,500,000 Secondary/Follow-On August 14, 2014</p>	<p>SMTIP, Inc.</p>  <p>\$11,500,000 Secondary/Follow-On January 30, 2014</p>
<p>InterCloud Systems, Inc.</p>  <p>\$5,800,000 Secondary/Follow-On October 30, 2013</p>	<p>Sorrento Therapeutics, Inc.</p>  <p>\$34,600,000 Secondary/Follow-On October 24, 2013</p>	<p>Advaxis, Inc.</p>  <p>\$26,500,000 Secondary/Follow-On October 16, 2013</p>	<p>Cancer Genetics, Inc.</p>  <p>\$16,100,000 Secondary/Follow-On August 13, 2013</p>	<p>Micronet Enertec Technologies, Inc.</p>  <p>\$9,300,000 Secondary/Follow-On April 23, 2013</p>	<p>Northwest Biotherapeutics, Inc.</p>  <p>\$13,800,000 Secondary/Follow-On December 7, 2012</p>	<p>Xplore Technologies Corp.</p>  <p>\$10,000,000 Secondary/Follow-On October 25, 2012</p>	<p>Trovagene, Inc.</p>  <p>\$10,600,000 Secondary/Follow-On May 29, 2012</p>

Past Nasdaq Up-Listing Offerings

**Galectin
Therapeutics, Inc.**



\$12,000,000
Secondary/Follow-On
March 23, 2012

**Synergy
Pharmaceuticals, Inc.**


















\$17,300,000
Follow-on Direct
December 1, 2011

Past Foreign Financings

<p>EZRaider</p>  <p>\$880,000 Debt Financing June 10, 2022</p>	<p>SaverOne 2014 Ltd.</p>  <p>\$13,000,000 U.S. Initial Public Offering June 2, 2022</p>	<p>OKYO Pharma Ltd.</p>  <p>\$2,500,000 Follow-On Offering May 16, 2022</p>	<p>Snow Lake Resources Ltd.</p>  <p>\$18,000,000 Follow-On Offering April 7, 2022</p>	<p>Permex Petroleum Corporation</p>  <p>\$7,500,000 Private Placement March 28, 2022</p>	<p>OMNIQ Corp.</p>  <p>\$8,500,000 Debt Financing March 25, 2022</p>	<p>Piedmont Lithium Inc.</p>  <p>\$130,800,000 Follow-On Offering March 22, 2022</p>	<p>Snow Lake Resources Ltd.</p>  <p>\$27,600,000 Initial Public Offering November 18, 2021</p>
<p>Siyata Mobile Inc.</p>  <p>\$6,000,000 Debt Financing October 27, 2021</p>	<p>Draganfly Inc.</p>  <p>\$20,000,000 Follow-On Offering July 29, 2021</p>	<p>Pyxis Tankers, Inc.</p>  <p>\$6,200,000 7.75% Series A Cumulative Convertible Preferred Stock July 14, 2021</p>	<p>OMNIQ Corp.</p>  <p>\$13,800,000 Private Placement July 8, 2021</p>	<p>BriaCell Therapeutics Corp.</p>  <p>\$27,000,000 Private Placement June 3, 2021</p>	<p>Save Foods, Inc.</p>  <p>\$12,000,000 Follow-On Offering May 13, 2021</p>	<p>Piedmont Lithium Limited</p>  <p>\$122,500,000 Follow-On Offering March 23, 2021</p>	<p>BriaCell Therapeutics Corp.</p>  <p>\$28,700,000 Follow-On Offering February 23, 2021</p>
<p>Pyxis Tankers, Inc.</p>  <p>\$25,000,000 Private Placement February 17, 2021</p>	<p>Nano Dimension Ltd.</p>  <p>\$500,000,000 Registered Direct February 15, 2021</p>	<p>Nano Dimension Ltd.</p>  <p>\$332,500,000 Nano Dimension Ltd. January 13, 2021</p>	<p>Nano Dimension Ltd.</p>  <p>\$250,000,000 Registered Direct December 27, 2020</p>	<p>Nano Dimension Ltd.</p>  <p>\$180,000,000 Registered Direct December 6, 2020</p>	<p>Nano Dimension Ltd.</p>  <p>\$60,000,000 Registered Direct November 29, 2020</p>	<p>Vision Marine Technologies Inc.</p>  <p>\$27,600,000 Initial Public Offering November 23, 2020</p>	<p>Nano Dimension Ltd.</p>  <p>\$100,000,000 Registered Direct November 19, 2020</p>
<p>Nano Dimension Ltd.</p>  <p>\$50,200,000 Registered Direct October 26, 2020</p>	<p>Piedmont Lithium Ltd.</p>  <p>\$57,500,000 Follow-On Offering October 21, 2020</p>	<p>Pyxis Tankers Inc.</p>  <p>\$5,000,000 7.75% Series A Cumulative Convertible Preferred Stock October 8, 2020</p>	<p>Nano Dimension Ltd.</p>  <p>\$16,900,000 Registered Direct September 30, 2020</p>	<p>GreenPower Motor Company, Inc.</p>  <p>\$37,200,000 U.S. Initial Public Offering August 28, 2020</p>	<p>Tiziana Life Sciences plc</p>  <p>\$57,300,000 Registered Direct August 3, 2020</p>	<p>Piedmont Lithium Ltd.</p>  <p>\$20,500,000 Follow-On Offering June 8, 2020</p>	<p>Nano Dimension Ltd.</p>  <p>\$35,900,000 Registered Direct May 20, 2020</p>

Past Foreign Financings

<p>Medigus Ltd.</p>  <p>\$5,000,000 Follow-On Offering May 19, 2020</p>	<p>Nano Dimension Ltd.</p>  <p>\$13,300,000 Follow-On Offering April 22, 2020</p>	<p>Tiziana Life Sciences plc</p>  <p>\$20,000,000 ATM Offering April 10, 2020</p>	<p>Tiziana Life Sciences plc</p>  <p>\$10,000,000 Follow-On Offering March 12, 2020</p>	<p>Nano Dimension Ltd.</p>  <p>\$3,900,000 Follow-On Offering February 5, 2020</p>	<p>Immuron Limited</p>  <p>\$2,000,000 Follow-On Offering May 23, 2019</p>	<p>GreenPower Motor Company</p>  <p>\$4,000,000 Private Placement May 3, 2019</p>	<p>OMNIQ Corp.</p>  <p>\$5,000,000 Private Placement April 4, 2019</p>
<p>ElectraMeccanica Vehicles Corp.</p>  <p>\$12,000,000 Registered Direct March 26, 2019</p>	<p>ReWalk Robotics Ltd.</p>  <p>\$13,300,000 Follow-On Offering November 16, 2018</p>	<p>ElectraMeccanica Vehicles Corp.</p>  <p>\$8,500,000 Registered Direct November 7, 2018</p>	<p>Wize Pharma, Inc.</p>  <p>\$4,500,000 Private Placement October 23, 2018</p>	<p>OMNIQ Corp.</p>  <p>\$6,300,000 Merger Consultant October 11, 2018</p>	<p>ElectraMeccanica Vehicles Corp.</p>  <p>\$10,000,000 Follow-On Offering August 8, 2018</p>	<p>Immuron Limited</p>  <p>\$5,100,000 Private Placement March 14, 2018</p>	<p>Pyxis Tankers Inc.</p>  <p>\$4,800,000 Private Placement December 6, 2017</p>
<p>BiondVax Pharmaceuticals Ltd.</p>  <p>\$10,000,000 Follow-On Offering September 14, 2017</p>	<p>Immuron Limited</p>  <p>\$6,100,000 Initial Public Offering June 8, 2017</p>	<p>Collect Biotechnology Ltd.</p>  <p>\$8,400,000 Initial Public Offering July 29, 2016</p>	<p>Kitov Pharmaceuticals Holdings Ltd.</p>  <p>\$12,000,000 Secondary/Follow-On June 29, 2016</p>	<p>LabStyle Innovations Corp.</p>  <p>\$8,500,000 Secondary/Follow-On March 4, 2016</p>	<p>Kitov Pharmaceuticals Holdings Ltd.</p>  <p>\$13,000,000 Initial Public Offering November 20, 2015</p>	<p>Oasmia Pharmaceutical AB</p>  <p>\$10,400,000 Initial Public Offering October 23, 2015</p>	<p>One Horizon Group, Inc.</p>  <p>\$3,000,000 Secondary/Follow-On August 5, 2015</p>
<p>BiondVax Pharmaceuticals Ltd.</p>  <p>\$9,600,000 Initial Public Offering May 11, 2015</p>	<p>Top Ships, Inc.</p>  <p>\$21,300,000 Secondary/Follow-On June 6, 2014</p>	<p>BioBlast Pharma Ltd.</p>  <p>\$4,800,000 Private Placement February 6, 2014</p>	<p>Oramed Pharmaceuticals, Inc.</p>  <p>\$15,800,000 Registered Direct December 24, 2013</p>	<p>SuperCom Ltd.</p>  <p>\$13,800,000 Secondary/Follow-On December 19, 2013</p>	<p>RiT Technologies, Inc.</p>  <p>\$6,000,000 Secondary/Follow-On November 21, 2013</p>	<p>Alcobra Ltd.</p>  <p>\$38,000,000 Secondary/Follow-On October 24, 2013</p>	<p>Oramed Pharmaceuticals, Inc.</p>  <p>\$4,600,000 Registered Direct July 10, 2013</p>

01 02 03

Past Foreign Financings

LabStyle Innovations
Corp.



\$10,000,000

Private Placement

May 10, 2013

Selected M&A Experience

SECONDSIGHT

nanoprecision
medical

Merger Agreement
February 2022

\$57,500,000
Follow-On Offering
June 2021

\$27,900,000
Private Placement
March 2021

\$7,500,000
Follow-On Offering
April 2020

- > Second Sight Medical Products Inc. (Nasdaq: EYES) raised \$7.5 million April 2020 in a follow-on offering of common stock.
- > In March 2021, the Company raised an additional \$27.9 million in a private placement of common stock.
- > In June 2021, Second Sight raised an additional \$57.5 million in a follow-on offering of common stock priced at \$5.00 per share.
- > In February 2022, Second Sight announced a merger agreement with Nano Precision Medical to become a wholly-owned subsidiary of Second Sight.
- > Nano Precision Medical' lead program, NPM-119, is a near clinical stage GLP-1 receptor agonist which is being developed to treat patients with Type 2 diabetes for up to 6 months with a single, tiny subdermal implant.
- > ThinkEquity served as a financial advisor to Second Sight in connection with the merger agreement



HAGERTY®

\$115,000,000
Initial Public Offering
April 2021

\$3.13 Billion
Business Combination
December 2021

- > In April 2021, Aldel Financial, Inc. (NYSE: ADF) raised \$115 million in a common stock public offering which listed the Company onto the NYSE. ThinkEquity acted as sole book-running manager for the offering
- > The Company priced the initial public offering of 11,500,000 equity units at a public offering price of \$10.00 per unit, including the full exercise of the underwriter's over-allotment option.
- > In August 2021, Hagerty and Aldel Financial announced the merger agreement for Hagerty to become a publicly traded company. The transaction values Hagerty at a pro forma enterprise value of \$3.13 billion.
- > The business combination closed on December 2, 2021, and the common stock and warrants began trading on the NYSE under the ticker symbols "HGTY" and "HGTY.WS," respectively.
- > Hagerty (NYSE: HGTY) is a leading specialty insurance provider focused on the global automotive enthusiast market with a scalable, innovative membership model and robust offerings, including immersive events, media content and valuation tools.
- > ThinkEquity served as a financial advisor to Aldel in connection with the business combination.

01 02 03 04

Selected M&A Experience



\$14,600,000
Acquisition
August 2021

- > In August 2021, ProPhase Labs, Inc. (Nasdaq: PRPH), announced the acquisition of Nebula Genomics, a privately-owned personal genomics company.
- > The Company's recently formed subsidiary, ProPhase Precision Medicine, Inc., completed the acquisition for approximately \$14.6 million in a combination of ProPhase Labs common stock and cash.
- > The Company intends to integrate Nebula's whole genome sequencing services with the robust clinical diagnostic testing services already offered at ProPhase's CLIA-certified molecular testing laboratories.
- > ThinkEquity acted as advisor to ProPhase in the acquisition.



\$238,000,000
Initial Public Offering
September 2020

- > In September 2020, FG New America Acquisition Corp (NYSE: FGNA) raised \$238 million in a public offering which listed the Company onto the NYSE. ThinkEquity acted as a book-running manager for the offering.
- > The Company priced the initial public offering of 23,775,000 equity units at a public offering price of \$10.00 per unit, including the full exercise of the underwriter's over-allotment option.



\$800,000,000
Business Combination
July 2021

- > In July 2021, Opportunity Financial ("OppFi") and FG New America Acquisition Corp. announced the merger agreement for OppFi to become a publicly traded company. The transaction values OppFi at a pro forma enterprise value of \$800 million.
- > The business combination closed on July 20, 2021, and the common stock and warrants began trading on the NYSE under the ticker symbols "OPFI" and "OPFI WS," respectively.
- > OppFi (NYSE: OPFI) is a leading financial technology platform that powers banks to offer accessible products and a top-rated experience to everyday consumers.
- > ThinkEquity served as a capital markets advisor to FG New America Acquisition Corp.

Selected M&A Experience



\$2,840,000
Acquisition
June 2021

- In June 2021, Altamira Therapeutics Ltd (Nasdaq: CYTO) (f/k/a Auris Medical Holding) announced the acquisition of Trasir Therapeutics, Inc., an RNA Therapeutics Company.
- The consideration comprises 0.77 million common shares of Auris Medical Holding Ltd., the assumption of certain selling shareholders' cash outlays as well as a future share-based payment contingent on reaching a specific development milestone.
- The Company acquired Trasir's innovative peptide-based OligoPhore™ platform designed to enable extrahepatic delivery of oligonucleotides.
- Trasir's founder, Dr. Samuel Wickline, joined the leadership team as Chief Scientific Officer.
- ThinkEquity acted as advisor to Altamira in the acquisition.



\$70,000,000
Follow-On Offering
June 2021

\$209,500,000
Follow-On Offering
May 2021

\$5,000,000
Bridge Loan
March 2021

\$10,000,000
Initial Public Offering
July 2020

- 1847 Goedecker Inc. (NYSE American: GOED) raised \$10.0 million in July 2020 in an initial public offering of common stock which listed the Company on the NYSE American.
- In March 2021, the Company announced the closing of two 10% OID senior secured promissory notes for an aggregate of \$5 million in gross proceeds.
- In May and June 2021, Goedecker simultaneously closed a follow-on offering, debt financing, and an acquisition. In May 2021, Goedecker raised \$209.5 million in the follow-on offering of common stock and warrants. One month later, the Company raised \$70.0 million in debt financing and closed its acquisition of Appliances Connection, creating one of the largest pure-play online retailer of household appliances in the US.

Selected M&A Experience



\$78,000,000
Business Combination
December 2019

- In December 2019, Drone Aviation and ComSovereign Holdings Corp. (Nasdaq: COMS) announced a business combination valued at \$78 million.
- The combined organization will focus on the penetration of 5G Systems to new and existing global carrier customer base for fixed infrastructure and aerial mobile communications platforms.
- ThinkEquity acted as financial advisor to ComSovereign Corp.



\$46,900,000
Acquisition
December 2019

- In December 2019, Better Choice Company Inc. (NYSE: BTTR) announced the acquisition of Halo, Purely for Pets valued at \$47 million, of which \$23.5 million was paid in cash, \$15 million in junior subordinated purchaser notes, and \$8.5 million in common equity.
- ThinkEquity acted as financial advisor to Better Choice Company.

Past Transactions – Lead & Co-Managed

<p>SMTP, Inc.</p>  <p>\$3,800,000 Secondary/Follow-On August 6, 2015</p>	<p>One Horizon Group, Inc.</p>  <p>\$3,000,000 Secondary/Follow-On August 5, 2015</p>	<p>EyeGate Pharmaceuticals, Inc.</p>  <p>\$10,000,000 Secondary/Follow-On July 31, 2015</p>	<p>Cryoport, Inc.</p>  <p>\$6,500,000 Secondary/Follow-On July 23, 2015</p>	<p>CytRx Corporation</p>  <p>\$28,800,000 Secondary/Follow-On July 21, 2015</p>	<p>NephroGenex, Inc.</p>  <p>\$7,500,000 Secondary/Follow-On July 16, 2015</p>	<p>Ritter Pharmaceuticals, Inc.</p>  <p>\$20,000,000 Initial Public Offering June 24, 2015</p>	<p>Caladrius Biosciences, Inc. (fka NeoStem)</p>  <p>\$28,800,000 Secondary/Follow-On May 27, 2015</p>
<p>Manhattan Bridge Capital, Inc.</p>  <p>\$4,500,000 Secondary/Follow-On May 22, 2015</p>	<p>Jaguar Animal Health, Inc.</p>  <p>\$20,000,000 Initial Public Offering May 13, 2015</p>	<p>BiondVax Pharmaceuticals Ltd.</p>  <p>\$9,600,000 Initial Public Offering May 11, 2015</p>	<p>Professional Diversity Network, Inc.</p>  <p>\$5,000,000 Secondary/Follow-On April 16, 2015</p>	<p>Matinas Biopharma</p>  <p>\$10,000,000 Private Placement April 10, 2015</p>	<p>InterCloud Systems, Inc</p>  <p>\$15,000,000 Credit Facility March 23, 2015</p>	<p>Heat Biologics, Inc.</p>  <p>\$12,300,000 Secondary/Follow-On March 10, 2015</p>	<p>CVSL, Inc.</p>  <p>\$20,000,000 Secondary/Follow-On February 26, 2015</p>
<p>CollabRx, Inc.</p>  <p>\$3,500,000 Secondary/Follow-On February 25, 2015</p>	<p>CollabRx, Inc.</p>  <p>\$5,500,000 Secondary/Follow-On February 19, 2015</p>	<p>Dance Biopharm Inc.</p>  <p>\$9,500,000 Private Placement February 18, 2015</p>	<p>Signal Genetics, Inc.</p>  <p>\$10,400,000 Secondary/Follow-On February 17, 2015</p>	<p>Snap Interactive, Inc.</p>  <p>\$3,000,000 Private Placement February 17, 2015</p>	<p>EyeGate Pharmaceuticals, Inc.</p>  <p>\$4,100,000 Initial Public Offering February 12, 2015</p>	<p>Biocept, Inc.</p>  <p>\$18,000,000 Secondary/Follow-On February 9, 2015</p>	<p>Intellitect Mobilisa, Inc.</p>  <p>\$8,500,000 Secondary/Follow-On January 8, 2015</p>
<p>Stemline Therapeutics, Inc.</p>  <p>\$58,900,000 Secondary/Follow-On January 7, 2015</p>	<p>Abeona Therapeutics, Inc. (fka PlasmaTech Biopharmaceuticals)</p> <p>\$14,000,000 Secondary/Follow-On December 18, 2014</p>	<p>AtheroNova, Inc.</p>  <p>\$3,000,000 Secondary/Follow-On October 28, 2014</p>	<p>InterCloud Systems, Inc.</p>  <p>\$44,300,000 M&A October 10, 2014</p>	<p>DT Asia Investments Limited</p> <p>\$60,000,000 Initial Public Offering September 30, 2014</p>	<p>Collectar Biosciences, Inc.</p>  <p>\$12,500,000 Secondary/Follow-On August 14, 2014</p>	<p>American DG Energy, Inc.</p>  <p>\$4,000,000 Secondary/Follow-On August 6, 2014</p>	<p>Manhattan Bridge Capital, Inc.</p>  <p>\$5,000,000 Secondary/Follow-On July 31, 2014</p>

01 02 03 04 05 06 07 08 09 10

Past Transactions – Lead & Co-Managed

<p>Medical Transcription Billing, Corp.</p>  <p>\$20,400,000 Initial Public Offering July 23, 2014</p>	<p>1347 Capital Corp.</p>  <p>\$40,000,000 Initial Public Offering July 16, 2014</p>	<p>Professional Diversity Network, Inc.</p>  <p>\$40,000,000 M&A July 14, 2014</p>	<p>GlobeImmune, Inc.</p>  <p>\$15,000,000 Initial Public Offering July 1, 2014</p>	<p>Garnero Group Acquisition Company</p> <p>\$125,000,000 Initial Public Offering June 25, 2014</p>	<p>China Biologic Products, Inc.</p>  <p>\$58,900,000 Secondary/Follow-On June 19, 2014</p>	<p>CollabRx, Inc.</p>  <p>\$1,800,000 Secondary/Follow-On June 19, 2014</p>	<p>Signal Genetics, Inc.</p>  <p>\$8,500,000 Initial Public Offering June 17, 2014</p>
<p>1347 Property Insurance Holdings, Inc.</p>  <p>\$23,000,000 Secondary/Follow-On June 10, 2014</p>	<p>Top Ships, Inc.</p>  <p>\$21,300,000 Secondary/Follow-On June 6, 2014</p>	<p>Corbus Pharmaceuticals Holdings, Inc</p>  <p>\$10,300,000 Private Placement June 3, 2014</p>	<p>Sorrento Therapeutics, Inc.</p>  <p>\$28,800,000 Secondary/Follow-On May 14, 2014</p>	<p>InVivo Therapeutics Holdings Corp.</p>  <p>\$16,100,000 Secondary/Follow-On May 6, 2014</p>	<p>San Luis Facility Development Corporation</p> <p>\$26,100,000 New Issue May 1, 2014</p>	<p>Aldeyra Therapeutics, Inc.</p>  <p>\$12,000,000 Initial Public Offering May 1, 2014</p>	<p>1347 Property Insurance Holdings, Inc.</p>  <p>\$17,400,000 Initial Public Offering March 31, 2014</p>
<p>Advaxis, Inc.</p>  <p>\$14,100,000 Secondary/Follow-On March 26, 2014</p>	<p>Recro Pharma, Inc.</p>  <p>\$34,500,000 Initial Public Offering March 6, 2014</p>	<p>Ceres, Inc.</p>  <p>\$23,000,000 Secondary/Follow-On March 4, 2014</p>	<p>Semler Scientific, Inc.</p>  <p>\$10,000,000 Initial Public Offering February 20, 2014</p>	<p>GlobeImmune, Inc.</p>  <p>\$7,500,000 Private Placement February 13, 2014</p>	<p>NephroGenex, Inc.</p>  <p>\$37,200,000 Initial Public Offering February 10, 2014</p>	<p>BioBlast Pharma Ltd.</p>  <p>\$4,800,000 Private Placement February 6, 2014</p>	<p>Biocept, Inc.</p>  <p>\$19,000,000 Initial Public Offering February 4, 2014</p>
<p>SMTp, Inc.</p>  <p>\$11,500,000 Secondary/Follow-On January 30, 2014</p>	<p>CytRx Corporation</p>  <p>\$86,300,000 Secondary/Follow-On January 30, 2014</p>	<p>Kips Bay Medical, Inc.</p>  <p>\$4,200,000 Secondary/Follow-On January 23, 2014</p>	<p>Akers Biosciences, Inc.</p>  <p>\$15,000,000 Initial Public Offering January 23, 2014</p>	<p>Intellicheck Mobilisa, Inc.</p>  <p>\$6,100,000 Secondary/Follow-On January 8, 2014</p>	<p>Fusion Telecommunications Int'l, Inc.</p>  <p>\$44,000,000 Private Placement December 31, 2013</p>	<p>Oramed Pharmaceuticals, Inc.</p>  <p>\$15,800,000 Registered Direct December 24, 2013</p>	<p>Sorrento Therapeutics, Inc.</p>  <p>\$17,700,000 Block Trade December 19, 2013</p>

01 02 03 04 05 06 07 08 09 10

Past Transactions – Lead & Co-Managed

<p>SuperCom Ltd.</p>  <p>\$13,800,000 Secondary/Follow-On December 19, 2013</p>	<p>Cambridge Capital Acquisition Corporation</p>  <p>\$80,500,000 Initial Public Offering December 17, 2013</p>	<p>Opexa Therapeutics, Inc.</p>  <p>\$8,100,000 Secondary/Follow-On December 17, 2013</p>	<p>InterCloud Systems, Inc.</p>  <p>\$11,600,000 Private Placement December 13, 2013</p>	<p>Synthetic Biologics, Inc.</p>  <p>\$13,200,000 Secondary/Follow-On December 11, 2013</p>	<p>RiT Technologies, Inc.</p>  <p>\$6,000,000 Secondary/Follow-On November 21, 2013</p>	<p>xG Technologies, Inc.</p>  <p>\$10,000,000 Secondary/Follow-On November 13, 2013</p>	<p>InterCloud Systems, Inc.</p>  <p>\$5,800,000 Secondary/Follow-On October 30, 2013</p>
<p>Quartet Merger Corp.</p> <p>\$96,600,000 Initial Public Offering October 28, 2013</p>	<p>Sorrento Therapeutics, Inc.</p>  <p>\$34,600,000 Secondary/Follow-On October 24, 2013</p>	<p>Alcobra Ltd.</p>  <p>\$38,000,000 Secondary/Follow-On October 24, 2013</p>	<p>Cancer Genetics, Inc.</p>  <p>\$46,000,000 Secondary/Follow-On October 22, 2013</p>	<p>Advaxis, Inc.</p>  <p>\$26,500,000 Secondary/Follow-On October 16, 2013</p>	<p>CytRx Corporation</p>  <p>\$25,900,000 Secondary/Follow-On October 8, 2013</p>	<p>Caladrius Biosciences, Inc. (fka NeoStem)</p>  <p>\$40,300,000 Secondary/Follow-On October 3, 2013</p>	<p>Evoke Pharma, Inc.</p>  <p>\$29,000,000 Initial Public Offering September 25, 2013</p>
<p>Timberline Resources Corp.</p>  <p>\$2,200,000 Secondary/Follow-On September 4, 2013</p>	<p>Cancer Genetics, Inc.</p>  <p>\$16,100,000 Secondary/Follow-On August 13, 2013</p>	<p>Aastrom Biosciences, Inc.</p>  <p>\$9,000,000 Secondary/Follow-On August 13, 2013</p>	<p>Matinas Biopharma</p>  <p>\$15,000,000 Private Placement August 12, 2013</p>	<p>Opexa Therapeutics, Inc.</p>  <p>\$19,400,000 Secondary/Follow-On August 7, 2013</p>	<p>Vuzix Corporation</p>  <p>\$8,100,000 Secondary/Follow-On July 30, 2013</p>	<p>Box Ships, Inc.</p>  <p>\$13,400,000 Secondary/Follow-On July 24, 2013</p>	<p>Heat Biologics, Inc.</p>  <p>\$27,000,000 Initial Public Offering July 23, 2013</p>
<p>xG Technologies, Inc.</p>  <p>\$8,500,000 Initial Public Offering July 18, 2013</p>	<p>Oramed Pharmaceuticals, Inc.</p>  <p>\$4,600,000 Registered Direct July 10, 2013</p>	<p>Miller Energy Resources, Inc.</p>  <p>\$7,200,000 Secondary/Follow-On July 3, 2013</p>	<p>MedWorth Acquisition Corp.</p>  <p>\$52,800,000 Initial Public Offering June 26, 2013</p>	<p>Echo Therapeutics, Inc.</p>  <p>\$12,500,000 Secondary/Follow-On June 19, 2013</p>	<p>RCS Capital Corporation</p>  <p>\$50,000,000 Initial Public Offering June 5, 2013</p>	<p>The Industrial Development Authority Of the County of La Paz, Arizona</p> <p>\$91,200,000 New Issue May 29, 2013</p>	<p>Virtual Piggy, Inc</p>  <p>\$6,400,000 Private Placement May 28, 2013</p>





























01 02 03 04 05 06 07 08 09 10

Past Transactions – Lead & Co-Managed

<p>Willacy County Public Facility Corporation</p>  <p>\$20,500,000 New Issue May 28, 2013</p>	<p>Alcobra Ltd.</p>  <p>\$25,000,000 Initial Public Offering May 22, 2013</p>	<p>Stemline Therapeutics, Inc.</p>  <p>\$69,000,000 Secondary/Follow-On May 16, 2013</p>	<p>LabStyle Innovations Corp.</p>  <p>\$10,000,000 Private Placement May 10, 2013</p>	<p>Caladrius Biosciences, Inc. (fka NeoStem)</p>  <p>\$11,500,000 Secondary/Follow-On April 29, 2013</p>	<p>Micronet Enertec Technologies, Inc.</p>  <p>\$9,300,000 Secondary/Follow-On April 23, 2013</p>	<p>Selway Capital Acquisition Corp. and Healthcare Corp of America</p>  <p>\$60,000,000 Business Combination April 11, 2013</p>	<p>Cancer Genetics, Inc.</p>  <p>\$6,900,000 Initial Public Offering April 4, 2013</p>
<p>Rosetta Genomics Ltd.</p>  <p>\$5,900,000 Advisor March 22, 2013</p>	<p>Five Oaks Investment Corp.</p>  <p>\$60,500,000 Initial Public Offering March 21, 2013</p>	<p>Hercules Technology Growth Capital</p>  <p>\$98,800,000 Secondary/Follow-On March 7, 2013</p>	<p>Oculus Innovative Sciences, Inc.</p>  <p>\$3,500,000 Secondary/Follow-On March 6, 2013</p>	<p>Professional Diversity Network, Inc.</p>  <p>\$21,000,000 Initial Public Offering March 5, 2013</p>	<p>Imprimis Pharmaceuticals, Inc.</p>  <p>\$11,100,000 Secondary/Follow-On February 7, 2013</p>	<p>Echo Therapeutics, Inc.</p>  <p>\$11,800,000 Secondary/Follow-On January 31, 2013</p>	<p>Stemline Therapeutics, Inc.</p>  <p>\$38,200,000 Initial Public Offering January 29, 2013</p>
<p>Kips Bay Medical, Inc.</p>  <p>\$6,500,000 Secondary/Follow-On December 21, 2012</p>	<p>Echo Therapeutics, Inc.</p>  <p>\$3,500,000 Secondary/Follow-On December 20, 2012</p>	<p>Northwest Biotherapeutics, Inc.</p>  <p>\$13,800,000 Secondary/Follow-On December 7, 2012</p>	<p>Superconductor Technologies Inc.</p>  <p>\$3,200,000 Secondary/Follow-On December 7, 2012</p>	<p>Superconductor Technologies Inc.</p>  <p>\$3,200,000 Secondary/Follow-On November 20, 2012</p>	<p>AspenBio Pharmaceuticals, Inc.</p>  <p>\$4,100,000 Secondary/Follow-On November 15, 2012</p>	<p>Comstock Mining</p>  <p>\$8,100,000 Secondary/Follow-On November 13, 2012</p>	<p>Xplore Technologies Corp.</p>  <p>\$10,000,000 Secondary/Follow-On October 25, 2012</p>
<p>CytRx Corporation</p>  <p>\$23,000,000 Secondary/Follow-On October 18, 2012</p>	<p>Net Element International Inc. merger with Cazador Acquisition to form Net Element</p>  <p>\$350,000,000 M&A October 2, 2012</p>	<p>Ascent Solar Technologies, Inc.</p>  <p>\$11,000,000 Secondary/Follow-On September 19, 2012</p>	<p>Neuralstem, Inc.</p>  <p>\$7,000,000 Registered Direct September 13, 2012</p>	<p>PURE Bioscience, Inc.</p>  <p>\$4,200,000 Secondary/Follow-On September 11, 2012</p>	<p>IZEA Inc.</p>  <p>\$2,200,000 Secondary/Follow-On September 5, 2012</p>	<p>Neuralstem, Inc.</p>  <p>\$2,800,000 Secondary/Follow-On August 14, 2012</p>	<p>Rosetta Genomics Ltd.</p>  <p>\$31,600,000 Secondary/Follow-On August 2, 2012</p>

01 02 03 04 05 06 07 08 09 10

Past Transactions – Lead & Co-Managed

<p>Ampio Pharmaceuticals, Inc.</p>  <p>\$17,800,000 Secondary/Follow-On July 12, 2012</p>	<p>New York Mortgage Trust, Inc.</p>  <p>New York Mortgage Trust, Inc. \$30,200,000 Secondary/Follow-On July 11, 2012</p>	<p>AspenBio Pharmaceuticals, Inc.</p>  <p>\$12,200,000 Secondary/Follow-On June 19, 2012</p>	<p>Trovagene, Inc.</p>  <p>\$10,600,000 Secondary/Follow-On May 29, 2012</p>	<p>New York Mortgage Trust, Inc.</p>  <p>New York Mortgage Trust, Inc. \$18,300,000 Secondary/Follow-On May 25, 2012</p>	<p>Rosetta Genomics Ltd.</p>  <p>\$6,600,000 Registered Direct May 24, 2012</p>	<p>Rosetta Genomics Ltd.</p>  <p>\$2,200,000 Registered Direct May 16, 2012</p>	<p>IZEA Inc.</p>  <p>\$1,400,000 Private Placement May 15, 2012</p>
<p>Synergy Pharmaceuticals</p>  <p>\$51,800,000 Secondary/Follow-On May 4, 2012</p>	<p>Firsthand Technology Value Fund</p>  <p>\$118,800,000 Secondary/Follow-On April 19, 2012</p>	<p>Rosetta Genomics Ltd.</p>  <p>\$3,100,000 Registered Direct April 12, 2012</p>	<p>TCP Capital Corp.</p>  <p>\$84,800,000 Initial Public Offering April 4, 2012</p>	<p>Garza County Public Facility Corporation</p> <p>\$35,900,000 New Issue March 28, 2012</p>	<p>Galectin Therapeutics, Inc.</p>  <p>\$12,000,000 Secondary/Follow-On March 23, 2012</p>	<p>Arlington Asset Investment Corp.</p>  <p>\$41,900,000 Secondary/Follow-On March 22, 2012</p>	<p>BGS Acquisition Corp.</p> <p>\$40,000,000 Initial Public Offering March 21, 2012</p>
<p>NetSol Technologies, Inc.</p>  <p>\$6,700,000 Secondary/Follow-On March 1, 2012</p>	<p>InVivo Therapeutics Holdings, Inc.</p>  <p>\$20,000,000 Secondary/Follow-On February 16, 2012</p>	<p>GSV Capital Corp.</p>  <p>\$90,000,000 Secondary/Follow-On February 10, 2012</p>	<p>Comstock Mining</p>  <p>\$17,300,000 Secondary/Follow-On February 9, 2012</p>	<p>ChromaDex Corporation</p>  <p>\$11,200,000 Registered Direct January 31, 2012</p>	<p>New York Mortgage Trust, Inc.</p>  <p>New York Mortgage Trust, Inc. \$16,600,000 Follow-on Direct December 1, 2011</p>	<p>Selway Capital Acquisition Corp.</p>  <p>\$20,000,000 Initial Public Offering November 8, 2011</p>	<p>American Realty Capital Properties, Inc.</p>  <p>\$15,800,000 Secondary/Follow-On October 28, 2011</p>
<p>TowerStream Corporation</p>  <p>\$41,400,000 Secondary/Follow-On July 15, 2011</p>	<p>China Growth Equity Investment Ltd.</p> <p>\$50,000,000 Initial Public Offering May 26, 2011</p>	<p>IZEA Holdings Inc.</p>  <p>\$3,300,000 Private Placement May 24, 2011</p>	<p>NetSol Technologies, Inc.</p>  <p>M&A May 19, 2011</p>	<p>Universal Business Payment Solutions Acquisition Corporation</p>  <p>\$72,000,000 Initial Public Offering May 9, 2011</p>	<p>SMG Indium Resources Ltd.</p> <p>\$24,000,000 Initial Public Offering May 4, 2011</p>	<p>Mission NewEnergy Limited</p>  <p>\$25,100,000 Initial Public Offering April 20, 2011</p>	<p>Hyperdynamics Corporation</p>  <p>\$143,800,000 Secondary/Follow-On March 25, 2011</p>













01 02 03 04 05 06 07 08 09 10

Past Transactions – Lead & Co-Managed

<p>Prime Acquisition Corp.</p>  <p>\$36,000,000 Initial Public Offering March 24, 2011</p>	<p>Gulfport Energy Corporation</p>  <p>\$153,600,000 Secondary/Follow-On March 24, 2011</p>	<p>Endeavour International Corporation</p>  <p>\$110,000,000 Secondary/Follow-On March 24, 2011</p>	<p>Kips Bay Medical, Inc.</p>  <p>\$16,500,000 Initial Public Offering February 11, 2011</p>	<p>On Track Innovation, Ltd.</p>  <p>\$18,000,000 Secondary/Follow-On February 3, 2011</p>	<p>Kingold Jewelry, Inc.</p>  <p>\$23,000,000 Secondary/Follow-On January 14, 2011</p>	<p>GeoResources, Inc.</p>  <p>\$134,000,000 Secondary/Follow-On January 13, 2011</p>	<p>Sino Clean Energy, Inc.</p>  <p>\$33,000,000 Secondary/Follow-On December 22, 2010</p>
<p>Magic Software Enterprises Ltd.</p>  <p>\$21,200,000 Private Placement December 20, 2010</p>	<p>Ventrus Biosciences, Inc.</p>  <p>\$17,400,000 Initial Public Offering December 16, 2010</p>	<p>YM Biosciences Inc.</p>  <p>\$40,000,000 Secondary/Follow-On December 14, 2010</p>	<p>FlatWorld Acquisition Corp.</p>  <p>\$22,000,000 Initial Public Offering December 10, 2010</p>	<p>SKY-mobi Limited</p>  <p>\$58,000,000 Initial Public Offering December 10, 2010</p>	<p>Geron Corporation</p>  <p>\$87,000,000 Secondary/Follow-On December 7, 2010</p>	<p>Lizhan Environmental Corp.</p>  <p>\$10,000,000 Initial Public Offering November 19, 2010</p>	<p>Ascent Solar Technologies, Inc.</p>  <p>\$21,800,000 Secondary/Follow-On November 12, 2010</p>
<p>Triangle Petroleum Corporation</p>  <p>\$59,400,000 Secondary/Follow-On November 5, 2010</p>	<p>China Linen Textile Industry, Ltd.</p>  <p>\$7,000,000 Private Placement November 4, 2010</p>	<p>Exact Sciences Corporation</p>  <p>\$69,000,000 Secondary/Follow-On November 4, 2010</p>	<p>JinkoSolar Holding Co., Ltd.</p>  <p>\$126,000,000 Secondary/Follow-On November 4, 2010</p>	<p>China Dredging Group Company Ltd.</p>  <p>\$50,100,000 Private Placement October 29, 2010</p>	<p>Energy XXI (Bermuda) Limited</p>  <p>\$286,400,000 Secondary/Follow-On October 28, 2010</p>	<p>Cavico Corp.</p>  <p>\$2,100,000 Secondary/Follow-On October 27, 2010</p>	<p>Funtalk China Holdings Limited</p>  <p>\$49,000,000 Secondary/Follow-On October 26, 2010</p>
<p>Comstock Mining Inc</p>  <p>\$35,800,000 Private Placement October 21, 2010</p>	<p>Yuhe International, Inc.</p>  <p>\$25,200,000 Secondary/Follow-On October 20, 2010</p>	<p>OncoGenex Pharmaceuticals</p>  <p>\$50,000,000 Secondary/Follow-On October 19, 2010</p>	<p>Golden Minerals Company</p>  <p>\$75,000,000 Secondary/Follow-On October 7, 2010</p>	<p>Cazador Acquisition Corporation</p>  <p>\$46,000,000 Initial Public Offering October 7, 2010</p>	<p>SkyPeople Fruit Juice, Inc.</p>  <p>\$25,900,000 Secondary/Follow-On August 26, 2010</p>	<p>D Medical Industries Ltd</p>  <p>\$10,500,000 Initial Public Offering August 5, 2010</p>	<p>China Intelligent Lighting and Electronics, Inc.</p>  <p>\$10,100,000 Initial Public Offering June 17, 2010</p>





















01 02 03 04 05 06 07 08 09 10

Past Transactions – Lead & Co-Managed

<p>Universal Travel Group</p>  <p>\$20,000,000 Secondary/Follow-On June 16, 2010</p>	<p>57th Street General Acquisition Corp.</p>  <p>\$54,600,000 Initial Public Offering May 20, 2010</p>	<p>China Agritech, Inc.</p>  <p>\$23,000,000 Secondary/Follow-On April 29, 2010</p>	<p>China Jo-Jo Drugstores, Inc.</p>  <p>\$17,500,000 Secondary/Follow-On April 22, 2010</p>	<p>NIVS IntelliMedia Technology Group, Inc.</p>  <p>\$24,000,000 Secondary/Follow-On April 20, 2010</p>	<p>Lihua International Inc.</p>  <p>\$34,500,000 Secondary/Follow-On April 9, 2010</p>	<p>Southern China Livestock International, Inc.</p>  <p>\$7,600,000 Private Placement March 31, 2010</p>	<p>Golden Minerals Company</p>  <p>\$34,000,000 Secondary/Follow-On March 18, 2010</p>
<p>G. Willi-Food International Ltd.</p>  <p>\$20,000,000 Secondary/Follow-On March 11, 2010</p>	<p>SinoCoking Coal and Coke Chemical Industries, Inc.</p>  <p>\$44,000,000 Private Placement March 11, 2010</p>	<p>Duoyuan Global Water, Inc.</p>  <p>\$104,600,000 Secondary/Follow-On February 27, 2010</p>	<p>China Redstone Group</p>  <p>\$4,600,000 Private Placement February 22, 2010</p>	<p>Derma Sciences, Inc.</p>  <p>\$5,600,000 Secondary/Follow-On February 16, 2010</p>	<p>Fushi Cooperweld, Inc.</p>  <p>\$59,800,000 Secondary/Follow-On January 26, 2010</p>	<p>Andatee China Marine Fuel Services Corp.</p>  <p>\$22,700,000 Initial Public Offering January 26, 2010</p>	<p>Seanergy Maritime Holdings Corp.</p>  <p>\$30,000,000 Secondary/Follow-On January 26, 2010</p>
<p>Rex Energy Corp.</p>  <p>\$84,500,000 Secondary/Follow-On January 14, 2010</p>	<p>DJSP Enterprises, Inc.</p>  <p>M&A January 11, 2010</p>	<p>Funtalk China Holdings Limited</p>  <p>\$21,700,000 Secondary/Follow-On December 17, 2009</p>	<p>Crimson Exploration</p>  <p>\$100,000,000 Secondary/Follow-On December 16, 2009</p>	<p>Energy XXI (Bermuda) Limited</p>  <p>\$171,000,000 Secondary/Follow-On December 8, 2009</p>	<p>AuthentiDate Holding Corp</p>  <p>\$3,400,000 Private Placement December 8, 2009</p>	<p>ZIOPHARM Oncology Inc.</p>  <p>\$48,000,000 Secondary/Follow-On December 4, 2009</p>	<p>GeoResources, Inc.</p>  <p>\$30,600,000 Secondary/Follow-On November 24, 2009</p>
<p>China Cord Blood Corporation</p>  <p>\$20,000,000 Secondary/Follow-On November 19, 2009</p>	<p>GSME Acquisition Partners I</p> <p>\$36,000,000 Initial Public Offering November 19, 2009</p>	<p>American Lorain Corporation</p>  <p>\$12,000,000 Private Placement October 29, 2009</p>	<p>Shandong LongKang Juice Co.</p> <p>\$15,100,000 Private Placement October 22, 2009</p>	<p>China Agritech, Inc.</p>  <p>\$15,000,000 Private Placement October 20, 2009</p>	<p>ZST Digital Networks, Inc.</p>  <p>\$25,000,000 Secondary/Follow-On October 20, 2009</p>	<p>China Education Alliance, Inc.</p>  <p>\$19,800,000 Secondary/Follow-On September 30, 2009</p>	<p>ATP Oil & Gas Corporation</p>  <p>\$98,100,000 Secondary/Follow-On September 23, 2009</p>

01 02 03 04 05 06 07 08 09 10

Past Transactions – Lead & Co-Managed

<p>Wave2Wave Communications</p>  <p>\$9,000,000 Debt Replacement Facility September 8, 2009</p>	<p>Lihua International Inc.</p>  <p>\$10,400,000 Initial Public Offering September 4, 2009</p>	<p>MannKind Corporation</p>  <p>\$54,400,000 Secondary/Follow-On August 5, 2009</p>	<p>FreeSeas, Inc.</p>  <p>\$18,100,000 Secondary/Follow-On July 22, 2009</p>	<p>Cell Therapeutics, Inc.</p>  <p>\$43,700,000 Secondary/Follow-On July 22, 2009</p>	<p>Skystar Bio-Pharmaceuticals Co.</p>  <p>\$20,900,000 Secondary/Follow-On June 30, 2009</p>	<p>Cyalume Light Technology</p>  <p>December 29, 2008</p>	<p>Pantheon China Acquisition Corp. Merger with China Corp Blood Corp</p>  <p>\$28,000,000 Bridge Loan December 10, 2008</p>
<p>Seanergy Maritime Holdings Corp.</p>  <p>\$395,300,000 M&A August 27, 2008</p>	<p>SmartHeat, Inc.</p>  <p>\$5,700,000 Private Placement July 8, 2008</p>	<p>Sequenom, Inc.</p>  <p>\$85,300,000 Secondary/Follow-On June 25, 2008</p>	<p>NetSol Technologies, Inc.</p>  <p>Dual Listing June 16, 2008</p>	<p>China Fundamental Acquisition Corp.</p> <p>\$30,000,000 Initial Public Offering May 15, 2008</p>	<p>BPW Acquisition Corp.</p> <p>\$350,000,000 Initial Public Offering February 26, 2008</p>	<p>Overture Acquisition Corp.</p> <p>\$150,000,000 Initial Public Offering January 30, 2008</p>	<p>Trian Acquisition I Corp.</p>  <p>\$800,000,000 Initial Public Offering January 23, 2008</p>
<p>Asia Special Situation Acquisition</p>  <p>\$100,000,000 Initial Public Offering January 16, 2008</p>	<p>United Refining Energy Corp.</p>  <p>\$450,000,000 Initial Public Offering December 11, 2007</p>	<p>Global Consumer Acquisition Corp.</p>  <p>\$300,000,000 Initial Public Offering November 21, 2007</p>	<p>2020 ChinaCap Acquirco, Inc.</p>  <p>\$60,000,000 Initial Public Offering November 9, 2007</p>	<p>Secure America Acquisition Corp.</p> <p>\$80,000,000 Initial Public Offering October 23, 2007</p>	<p>TM Entertainment and Media, Inc.</p>  <p>\$72,000,000 Initial Public Offering October 17, 2007</p>	<p>Stone Tan China Acquisition Corp.</p> <p>\$240,000,000 Initial Public Offering October 15, 2007</p>	<p>FMG Acquisition Corp.</p>  <p>\$36,000,000 Initial Public Offering October 4, 2007</p>
<p>Seanergy Maritime Holdings Corp.</p>  <p>\$220,000,000 Initial Public Offering September 24, 2007</p>	<p>InterAmerican Acquisition Group</p> <p>\$40,000,000 Initial Public Offering September 5, 2007</p>	<p>ImaRx Therapeutics Inc.</p> <p>\$15,000,000 Initial Public Offering July 25, 2007</p>	<p>Alyst Acquisition Corp.</p> <p>\$56,000,000 Initial Public Offering June 29, 2007</p>	<p>Response Genetics, Inc.</p>  <p>\$21,000,000 Initial Public Offering June 4, 2007</p>	<p>TransTech Services Partners</p>  <p>\$36,000,000 Initial Public Offering May 23, 2007</p>	<p>Arcade Acquisition Corporation</p> <p>\$60,000,000 Initial Public Offering May 21, 2007</p>	<p>China Healthcare Acquisition Corp</p>  <p>\$51,000,000 Initial Public Offering April 19, 2007</p>

01 02 03 04 05 06 07 08 09 10

Past Transactions – Lead & Co-Managed

<p>PinPoint Advance Corp</p>  <p>\$36,000,000 Initial Public Offering April 19, 2007</p>	<p>Alpha Security Group Corporation</p>  <p>\$60,000,000 Initial Public Offering March 23, 2007</p>	<p>Oceanaut, Inc.</p>  <p>\$150,000,000 Initial Public Offering March 1, 2007</p>	<p>Dekania Corp.</p>  <p>\$97,000,000 Initial Public Offering February 1, 2007</p>	<p>Oculus Innovative Sciences, Inc.</p>  <p>\$24,200,000 Initial Public Offering January 26, 2007</p>	<p>Fuwei Films (Holdings) Co.</p>  <p>\$31,000,000 Initial Public Offering December 18, 2006</p>	<p>SORL Auto Parts, Inc</p>  <p>\$31,100,000 Secondary/Follow-On November 27, 2006</p>	<p>Thermage, Inc.</p>  <p>\$42,000,000 Initial Public Offering November 9, 2006</p>
<p>RRSat Global Communication</p>  <p>\$47,500,000 Initial Public Offering November 1, 2006</p>	<p>Ivivi Technology, Inc.</p>  <p>\$15,000,000 Initial Public Offering October 18, 2006</p>	<p>Millennium India Acquisition Company</p> <p>\$58,000,000 Initial Public Offering July 20, 2006</p>	<p>Energy Infrastructure Acquisition Corp.</p>  <p>\$202,500,000 Initial Public Offering July 18, 2006</p>	<p>Affinity Media International Corp.</p>  <p>\$16,500,000 Initial Public Offering June 5, 2006</p>	<p>Community Bankers Acquisition Corp.</p> <p>\$60,000,000 Initial Public Offering June 5, 2006</p>	<p>Minrad International, Inc.</p>  <p>\$32,500,000 Secondary/Follow-On May 23, 2006</p>	<p>Compass Diversified Trust</p>  <p>\$202,500,000 Initial Public Offering May 10, 2006</p>
<p>JK Acquisition Corp.</p> <p>\$69,000,000 Initial Public Offering April 11, 2006</p>	<p>Incredimail, Ltd.</p>  <p>\$21,500,000 Initial Public Offering January 30, 2006</p>	<p>Star Maritime Acquisition Corp.</p>  <p>\$188,700,000 Initial Public Offering December 15, 2005</p>	<p>Key Hospitality Acquisition Corp.</p> <p>\$48,000,000 Initial Public Offering October 20, 2005</p>	<p>BioDelivery Sciences Int'l</p>  <p>\$8,800,000 Secondary/Follow-On September 29, 2005</p>	<p>Ad Venture Partners</p> <p>\$54,000,000 Initial Public Offering August 26, 2005</p>	<p>Healthcare Acquisition Corp.</p>  <p>\$72,000,000 Initial Public Offering July 28, 2005</p>	<p>Comtech Group</p>  <p>\$40,400,000 Secondary/Follow-On July 15, 2005</p>
<p>Gentium S.p.A</p>  <p>\$24,800,000 Initial Public Offering June 16, 2005</p>	<p>Coffee Holding Co., Inc.</p>  <p>\$9,200,000 Initial Public Offering May 2, 2005</p>	<p>Interchange Inc.</p>  <p>\$22,000,000 Initial Public Offering October 19, 2004</p>	<p>GuruNet Corp.</p>  <p>\$11,800,000 Initial Public Offering October 13, 2004</p>	<p>Newtek Business Services, Inc.</p>  <p>\$25,000,000 Secondary/Follow-On June 28, 2004</p>	<p>Manhattan Pharmaceuticals</p>  <p>\$10,000,000 Private Placement Sole Placement Agent</p>	<p>Acacia Combimatrix Corp.</p>  <p>\$4,900,000 Private Placement Sole Placement Agent</p>	<p>TeamStaff, Inc.</p>  <p>\$4,300,000 Private Placement Sole Placement Agent</p>

01 02 03 04 05 06 07 08 09 10

Past Transactions – Lead & Co-Managed

<p>ADM Tronics Unlimited</p>  <p>\$6,100,000 Private Placement Sole Placement Agent</p>	<p>Starfire Systems, Inc.</p>  <p>\$3,000,000 Private Placement Co-Placement Agent</p>	<p>pSivida LTD</p>  <p>\$15,000,000 Private Placement Co-Placement Agent</p>	<p>Velocity Express Corporation</p>  <p>\$45,000,000 Private Placement Co-Placement Agent</p>	<p>Xstream Beverage Network, Inc.</p>  <p>\$17,500,000 Private Placement Sole Placement Agent</p>	<p>Drugmax, Inc.</p>  <p>\$17,000,000 Private Placement Co-Placement Agent</p>	<p>Association of Volleyball Professionals</p>  <p>\$5,000,000 Private Placement Sole Placement Agent</p>	<p>Altair Nanotechnologies</p>  <p>\$20,250,000 Shelf Offering Sole Placement Agent</p>
<p>PacificNet Inc.</p>  <p>\$8,000,000 Convertible Debt Private Placement Co-Placement Agent</p>	<p>Getium S.p.A.</p>  <p>\$10,900,000 Private Placement Co-Placement Agent</p>	<p>Diguang Electronics</p>  <p>\$12,000,000 Private Placement Co-Placement Agent</p>	<p>PRB Gas Transportation</p>  <p>\$22,000,000 Private Placement Co-Placement Agent</p>	<p>ImaRx Therapeutics</p>  <p>\$14,200,000 Private Placement Co-Placement Agent</p>	<p>Jed Oil Inc.</p>  <p>\$34,300,000 Private Placement Co-Placement Agent</p>	<p>Netsol Technologies, Inc.</p>  <p>\$5,500,000 Private Placement Sole Placement Agent</p>	<p>Debt Resolve, Inc.</p>  <p>\$2,600,000 Bridge Financing Co-Placement Agent</p>
<p>Pipeline Data, Inc.</p>  <p>\$37,000,000 Convertible Debt Private Placement Sole Placement Agent</p>	<p>Cel-Sci Corporation</p>  <p>\$8,300,000 Private Placement Sole Placement Agent</p>	<p>IXI Mobile</p>  <p>\$20,000,000 Bridge Financing Co-Placement Agent</p>	<p>Hyperspace Communications, Inc.</p>  <p>\$9,500,000 Private Placement Sole Placement Agent</p>	<p>Asiamart, Inc.</p>  <p>\$3,100,000 Private Placement Co-Placement Agent</p>	<p>Signalife, Inc.</p>  <p>\$2,900,000 Private Placement Sole Placement Agent</p>	<p>Universal Guardian Holdings, Inc.</p>  <p>\$6,000,000 Private Placement Sole Placement Agent</p>	<p>Conmed Healthcare Management, Inc.</p>  <p>\$15,000,000 Private Placement Sole Placement Agent</p>
<p>Telestone Technologies Corp.</p>  <p>\$6,000,000 Private Placement Sole Placement Agent</p>	<p>Velcera, Inc.</p>  <p>\$9,900,000 Private Placement Sole Placement Agent</p>	<p>IsoRay, Inc.</p>  <p>\$16,500,000 Private Placement Co-Placement Agent</p>	<p>Oncovista, Inc.</p>  <p>\$6,800,000 Private Placement Sole Placement Agent</p>	<p>DigitalFX International, Inc.</p>  <p>\$7,000,000 Private Placement Sole Placement Agent</p>			

01 02 03 04 05 06 07 08 09 10

Disclaimer

Investment products are made available through ThinkEquity, member NYSE, FINRA (www.finra.org) & SIPC (www.sipc.org).

These documents are for informational purposes only. The information does not constitute a solicitation or an offer to buy or sell any security.

Transactions occurring before April 1, 2018, were executed by the team prior to joining ThinkEquity LLC and selected transactions may not be an all-inclusive list.

This information is confidential and intended solely for the use of ThinkEquity and the client or prospective client to whom it has been delivered. It is not to be reproduced or distributed to any person except to the client's professional advisor.

Before making an investment decision, you should carefully read the applicable offering memorandum or prospectus which contains important disclosures regarding risks, fees, and expenses. Any third party information used in this document has been obtained from various published and unpublished sources considered to be reliable. However, ThinkEquity cannot guarantee its accuracy or completeness and thus, does not accept liability for any direct or consequential losses arising from its use.

Past performance is no guarantee of future results. The investment return and principal value of an investment can fluctuate with changes in market conditions.

Contact Us

ThinkEquity



Member NYSE, FINRA, SIPC



Address

17 State Street, 22nd Floor
New York, NY 10004



Phone

646-968-9355



Email

info@think-equity.com